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Summary 
ChemR23 is a G-protein coupled receptor expressed on monocytes and macrophages as well 
as on adipocytes. It binds two ligands, the peptide chemerin and the omega-3 fatty acid 
derived resolvin E1 (RvE1). Chemerin is present in inflamed tissue and acts as a 
chemoattractant of ChemR23 expressing leukocytes. Chemerin is also an adipokine secreted 
by mature adipocytes and regulating preadipocyte maturation. The second ChemR23 ligand 
RvE1 induces resolution of inflammation. It has been shown protective in many animal 
models of chronic and acute inflammation and is believed to be one of the mediators of the 
beneficial properties of dietary omega-3 fatty acids. As a receptor of chemerin and RvE1, 
ChemR23 plays a role in macrophage immigration to the inflamed areas, in inflammation 
resolution as well as in adipogenesis and might present a connection between inflammation 
and adiposity. Yet, little is known about the regulation of ChemR23 during different stages of 
inflammation or in different macrophage phenotypes.  
Our results show that ChemR23 is predominantly expressed in the inflammatory M1 
macrophages, which are attracted via the chemerin-ChemR23 axis. In contrast, the anti-
inflammatory M2 macrophages do not express the receptor and are not responsive to 
ChemR23 mediated signaling. The proresolving action of RvE1 must therefore be on 
inflammatory M1 or naive macrophages. Our data show that RvE1 treatment of M1 
macrophages increased transcription of the anti-inflammatory cytokines IL-10 but does not 
cause full re-polarization into M2 phenotype. We further show that ChemR23 is transcribed 
from 2 transcription starts in monocytes and macrophages and that the usage of promoters 
upstream of these starts differs in naive and classically activated cells. As a results, several 
ChemR23 mRNA isoforms differing in the 5´untranslated region are transcribed in monocytes 
and naive and activated macrophages likely enabling phenotype specific regulation of mRNA 
translation. 
Plasma levels of the ChemR23 ligand chemerin have been associated with obesity, chronic 
inflammation and metabolic syndrome - risk factors for coronary artery disease (CAD). We 
studied possible direct association of chemerin levels with CAD. Our data show that in CAD 
patients not taking low dose aspirin, plasma chemerin levels are significantly higher than in 
patients on low dose aspirin and in healthy controls. On cellular level, we show that 
inflammatory cytokines typically secreted by inflammatory M1 macrophages increase 
chemerin production in adipocytes. Low dose aspirin treatment has no direct impact on 
chemerin production in adipocytes in vitro but decreases inflammatory cytokine secretion in 
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M1 macrophages thus decreasing the stimulus for chemerin production in adipocytes. Our 
data indicate that chemerin levels might reflect the inflammatory status of adipose tissue and 
that even low dose aspirin has anti-inflammatory effect on M1 macrophages.  
CAD is caused by the formation of atherosclerotic plaques in the aterial intima, in which 
inflammation plays an important role. Polymorphisms in the ChemR23 gene may have an 
impact on inflammation and thus on the onset and/or course of CAD. We sequenced the 
coding region of ChemR23 gene and of the two promoters used in monocytes and 
macrophages in a CAD case-control study and analyzed the associtaion of idenfied 
polymorphisms with CAD. Our results suggest an associtaion of the promoter polymorphism 
rs1399820 and a trend for associtation of the non-synonymous polymorphism rs192034694 in 
the coding region with CAD. While our data indicate, that rs192034694 might have an impact 
on ChemR23 functionality, a functional assay would have to confirm this notion.  
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Zusammenfassung 
ChemR23 ist ein G-Protein gekoppelter Rezeptor, welcher von Monozyten und Makrophagen 
wie auch von Adipozyten exprimiert wird. ChemR23 bindet zwei Liganden: das Peptid 
Chemerin und das von den Omega-3-Fettsäuren abstammende Resolvin E1 (RvE1). 
Chemerin ist in entzündetem Gewebe vorhanden und verhält sich als Chemoattraktant für 
Leukozyten, die ChemR23 exprimieren. Zusätzlich ist Chemerin ein Adipokin, welches von 
reifen Adipozyten sezerniert wird und die Reifung der Präadipozyten reguliert. Der zweite 
ChemR23 Ligand, RvE1, veranlasst die Resolution der Entzündungsreaktion. RvE1 hatte eine 
schützende Wirkung in verschiedenen Tiermodellen der chronischen und akuten Entzündung 
und es wird vermutet, dass es einer der Vermittler der nutzbringenden Eigenschaften der 
Omega-3-Fettsäuren ist. 
Als Chemerin und RvE1 Rezeptor spielt ChemR23 eine wichtige Rolle bei der Migration von 
Makrophagen in das Entzündete Gewebe, bei der Resolution der Entzündung, wie auch bei 
der Adipozytenreifung. Allerdings ist bis jetzt die ChemR23 Regulation während den 
verschiedenen Entzündungsstadien wie auch in den unterschiedlichen Makrophagen 
Phänotypen relativ unbekannt. 
Unsere Ergebnisse zeigen, dass ChemR23 überwiegend in den pro-inflammatorischen M1 
Makrophagen exprimiert wird, welche über die Chemerin-ChemR23 Achse angezogen 
werden. Im Gegensatz dazu exprimieren die anti-inflammatorische M2 Makrophagen kein 
ChemR23 und können somit nicht auf das Chemerin oder RvE1 Signal eingehen. Die 
proresolutive Aktion von RvE1 kann daher nur auf M1 oder auf unaktivierte Makrophagen 
wirken. Unsere Daten weisen darauf hin, dass in RvE1 behandelten M1 Makrophagen die 
Transkriptionsrate des anti-inflammatorisches Zytokines IL-10 erhöht ist ohne dass eine volle 
Repolarizierung in M2 Phänotyp stattfindet. Zusätzlich deuten wir darauf hin, dass ChemR23 
von zwei unterschiedlichen Transkriptionsstartpunkten in Monozyten und Makrophagen 
transkribiert wird. Die Nutzung der Promotoren unterscheidet sich zwischen den naiven und 
M1 aktivierten Zellen. Somit werden unterschiedlich lange Isoformen von ChemR23 mRNA 
erhalten, die sich in der 5´nicht-transkribierten Region unterscheiden. Vermutlich ermöglicht 
diese Diversifikation eine Phänotyp spezifische Regulation der Transkription und Translation.  
Die Chemerin Plasmakonzentration wurde mit verschiedenen Risikofaktoren für die koronare 
Herzkrankheit verknüpft, namentlich Adipositas, chronische Entzündung und metabolisches 
Syndrom. Wir haben untersucht, ob die Chemerin Plasmakonzentration direkt mit der 
koronaren Herzkrankheit verbunden ist. Wir zeigen, dass Chemerinkonzentration in Patienten 
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mit koronare Herzkrankheit, die kein niedrigdosiertes Aspirin zu sich nehmen, signifikant 
erhöht ist. Auf zellulärer Ebene zeigen wir, dass Inflammatorische Zytokine, die 
typischerweise von M1 Makrophagen sezerniert werden, die Chemerinproduktion in den 
Adipozyten erhöhen. Behandlung mit niedrigdosiertem Aspirin hat keine direkte Auswirkung 
auf die Chemerinproduktion in den Adipozyten in vitro, erniedrigt allerdings die Produktion 
der inflammatorischen Zytokine in den M1 Makrophagen. Folglich sinkt dann der Stimulus 
für die Chemerinproduktion in den Adipozyten. Unsere Werte weisen darauf hin, dass die 
Chemerinkonzentration den Entzündungsstatus des Fettgewebes widerspiegelt und dass selbst 
niedrigdosiertes Aspirin ein Anti-Entzündungseffekt auf M1 Makrophagen hat. 
Entstehung und Entwicklung von atherosklerotischen Plaques, die koronaren Herzkrankheiten 
verursachen, ist verbunden mit dem Entzündungsprozess in der Plaque. Polymorphismen im 
ChemR23 Gen könnten einen Einfluss auf den Entzündungsprozess und somit auf den 
Krankheitsverlauf von koronaren Herzkrankheiten haben. Wir haben die Protein kodierende 
Region von ChemR23, wie auch die in Monozyten und Makrophagen aktiven Promotoren in 
einer Fall-Kontrolle Studie für koronare Herzkrankheiten sequenziert und untersucht of 
identifizierte Polymorphismen mit der koronaren Herzkrankheit verbunden sind. Der 
Promotorpolymorphismus rs1399820 zeigt einen deutlichen Zusammenhang mit koronaren 
Herzkrankheiten, wohingegen der funktionelle Polymorphismus rs192034694 nur eine 
Tendenz hat. Funktionelle Studien müssen durchgeführt werden, um den Einfluss der 
Polymorphismen auf die ChemR23 Transkription und Funktionalität zu zeigen. 
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1 Introduction 
1.1 Inflammation 
Inflammation is an essential protective response of the body to pathogen infection or tissue 
injury with the aim to remove the pathogen and/or damaged cells, and to return the tissue to 
homeostasis. Start of inflammation is marked with heat, redness, swelling and pain caused by 
increased blood flow, increased blood vessel permeability and inflammatory mediators 
sensitizing the local neural system in the affected area [1]. If inflammation is not resolved 
timely it can lead to tissue fibrosis and loss of function [2]. Impaired resolution of 
inflammation can furthermore lead to chronic inflammation, which is a key component of 
many diseases such as arthritis, inflammatory bowel disease and atherosclerosis [3]. 
1.1.1 Cellular basis of inflammation 
Inflammation is initiated when microbial particles or fragments of own damaged cells are 
recognized by the tissue resident antigen presenting cells (APCs) such as macrophages or 
dendritic cells [4]. They start rapidly secreting signaling molecules to attract further 
leukocytes from the blood stream. Neutrophils are the first leukocytes recruited to the site of 
inflammation [5]. They are responsible for killing and phagocytosis of the pathogens. 
Activated neutrophils secrete reactive oxygen species (ROS), reactive nitrogen species, and 
other cytotoxic molecules to kill pathogens and detoxify the cellular debris [6]. In addition, 
neutrophils can extrude so called neutrophil extracellular traps (NETs), which are composed 
of DNA and histones and proteins from neutrophil granules. NETs have recently been shown 
to trap microorganisms and promote the interaction of these microorganisms with the 
neutrophil granule derived proteins and their destruction [7].  
At the same time, mediators released from neutrophil granules attract monocytes from the 
circulation and activate surrounding endothelial cells to express adhesion molecules and 
chemoattractants facilitating monocyte extravasation [8]. Neutrophils are short-lived cells and 
phagocytosis of microbial particles or components of necrotic cells further induces their 
apoptosis [9]. Extravasation of monocytes to the site of inflammation is followed by their 
differentiation into macrophages, the main scavengers of apoptotic neutrophils [10]. Timely 
clearance of dead neutrophils is essential as cytotoxic substances contained within the 
neutrophils could lead to damage of the own tissue [11]. Phagocytosis of apoptotic 
neutrophils by macrophages leads to secretion of signals stopping further recruitment of 
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neutrophils and promoting the repair of adjacent tissue [2]. Finally macrophages are cleared 
by emigration into draining lymphatics [12].   
1.1.2 Macrophage subsets 
Macrophages play an important role in all stages of inflammation. They participate in its 
initiation by recognizing the pathogen and acting as APCs [4]. Subsequently they help 
detoxify and remove the pathogen. Finally, they play a key role in the resolution of 
inflammation and return of the affected tissue to homeostasis by removing apoptotic 
neutrophils and releasing molecules signaling for tissue repair [8]. To be able to fulfill all 
these functions, macrophages are very heterogeneous. They develop different phenotypes 
depending on the signals they receive from the environment. Several macrophage phenotypes 
with distinct functions have been described - the classically activated inflammatory M1 
macrophages and alternatively activated M2 macrophages [13,14]. In addition, each tissue 
harbors resident macrophages, which were named according to their location – microglia 
(brain), kupfer cells (liver), alveolar macrophages (lung) [15].  
M1 macrophages are important during the initiation of inflammation. They are activated by 
toll-like receptor (TLR) ligands such as the lipopolysacharide (LPS) a component of bacterial 
cell wall, and by T helper 1 (Th1) cell cytokines such as interferon-γ (IFN-γ) [4]. M1 
macrophages secrete high amounts of inflammatory cytokines (IL-1β, TNFα) and ROS and 
remove pathogens by phagocytosis. They also further promote Th1 responses [14]. 
In contrast, M2 macrophages have regulatory and anti-inflammatory functions with a role in 
resolution of inflammation and tissue repair. M2 macrophages are considered to be cells 
activated by IL-4 or IL-13 expressing high levels of the mannose receptor and secreting the 
anti-inflammatory cytokines IL-10 and TGFβ [16]. However, there is a range of M2-like 
phenotypes, which are adopted by macrophages in response to IL-10, TGFβ or 
glucocorticoids [14]. These cells share some but not all characteristics with M2 macrophages. 
It is not clear whether M2 macrophages differentiate from newly arrived monocytes during 
the end of inflammation, whether they are created by proliferation of resident macrophages 
upon stimulation by Th2 cell cytokine [17], or whether M1 macrophages switch their 
phenotype to M2. It has however been shown that macrophage polarization state is not 
definite and that macrophages are at least partially able to switch from one phenotype to 
another in vitro as well as in vivo [18,19]. 
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1.1.3 Chemokine and chemoattractant signaling 
The above described interplay of lymphocytes during the course of inflammation is 
coordinated by a complex network of cytokine and chemokine signaling. Tight regulation of 
chemokine and cytokine release and of their receptor expression on different cell types allows 
extreme fine-tuning of the inflammatory response.  
Chemotactic cytokines or chemokines are peptides, which are secreted by lymphocytes, 
epithelial and endothelial cells at specific time points of inflammation. Their activity can be 
further modified by cleavage by proteases such as metalloproteinases released from 
neutrophile granules [8]. Chemokines signal through G-protein coupled receptors (GPCRs) 
containing 7 membrane-spanning domains, differentially expressed on leukocytes, endothelial 
and epithelial cells. Chemokines are key in orchestrating the immigration of different types of 
leukocytes during all phases of inflammation – from initiation to resolution.  
At the beginning of inflammation, activated tissue macrophages and dendritic cells (DCs) 
secrete CXCL8 (IL-8), CXCL1 and CXCL2, which primarily attract neutrophils, and CCL2 
(also called monocyte chemoattractant protein - MCP-1) and CCL3/4 (also called macrophage 
inflammatory protein - MIP-1), which attract monocytes [10]. As neutrophils are very short-
lived, new cells have to be attracted throughout the time of inflammation. Attracted activated 
neutrophils secrete pro-inflammatory cytokines IL-1β and TNFα, which stimulate further the 
production of neutrophil attracting chemokines [8]. Furthermore, metalloproteinases secreted 
by macrophages, neutrophils and endothelial cells can cleave chemokines such as CXCL8 and 
CXCL1 to increase their chemotactic potency and so amplify the signal for neutrophil 
infiltration [20]. Neutrophils also produce mediators such as soluble complexes of IL-6 and its 
receptor IL-6R, which activate endothelial cells to express adhesion molecules and 
chemokines (e.g. CCL2). This promotes recruitment and extravasation of monocytes [21].  
During early resolution of inflammation new signaling molecules come into the play and  stop 
the recruitment of leukocytes and induce clearance of cellular debris. For example, increased 
expression of the chemokine receptor CXCR5 on apoptotic neutrophils leads to sequestration 
of CCL3 and CCL5 and thus reduction of infiltration of new neutrophils [7]. Phagocytosis of 
apoptotic neutrophils by macrophages leads to their secretion of anti-inflammatory cytokines 
TGFβ and IL-10 [22] and release of metalloproteinases, which inactivate chemokines by 
cleavage. Binding of these inactive chemokines to their receptors can lead to the receptor 
blocking and further dampening of inflammation [7].  
1.1.4 Lipid mediator signaling 
Pro-inflammatory lipid mediators 
Lipid mediators are further signaling molecules, which regulate inflammation. Prostaglandins 
and leukotrienes have been for long time appreciated for their pro-inflammatory actions [23]. 
They are generated in leukocytes from the essential omega-6 polyunsaturated fatty acid 
(PUFA) arachidonic acid through the cyclooxygenase (COX) and lipoxygenase (LOX) 
pathways, respectively (Figure 1.1). They act at distinct GPCRs, which are expressed on 
leukocytes and endothelial cells. Prostaglandin signaling leads to vasodilatation, fever and 
pain, leading to some of the cardinal signs of inflammation [1]. Leukotriene B4 is a potent 
chemoattractant of neutrophils, inducer of neutrophile granule release and of ROS production 
[24]. Prostaglandin synthesis is the target of probably the most widely used anti-inflammatory 
agent – aspirin and of further non-steroidal anti-inflammatory drugs such as indomethacin and 
ibuprofen. Aspirin blocks the synthesis of prostaglandins and thromboxane (TXA) by 
irreversible inhibition of both COX isoforms [25].  
 
Peroxidase
PGH2
Prostaglandins
Leukotrienes
Figure 1.1: Synthesis of leukotrienes and prostaglandins 
Adapted from [1]. Leukotrienes and prostaglandins are not stored within cells, but are 
synthesized as required in response to hormonal stimuli. First, arachidonic acid is released 
from the cellular phospholipids by the action of the enzyme phospholipase A2. Next, the free 
fatty acid is converted to the precursor of prostaglandin PGH2 by a sequential reaction with 
cyclooxygenases (COX-1 or COX-2) and a peroxidase, or to the precursor of the leukotrienes 
5-HPETE by the 5-LOX [26]. In subsequent reactions with series of different cell specific 
enzymes, prostaglandins and leukotrienes are then synthesized from their precursors. 
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Anti-inflammatory and pro-resolving lipid mediators 
In the 1990´s, the lipoxins have been discovered as a novel class of lipid mediators, which had 
anti-inflammatory and pro-resolving properties [27]. Lipoxins are typically synthesized from 
arachidonic acid by trans-cellular pathways. The cell-cell interaction is needed because few 
cell types express both of the required LOXes. For example, lipoxins are produced during the 
interaction of infiltrating neutrophils (which express 5-LOX) and epithelial monocytes (which 
express 15-LOX) in inflamed target organs, or after interaction of neutrophils with platelets 
(which express 12-LOX) [28]. Using a murine dorsal air pouch model of spontaneously 
resolving inflammation, it has been documented that while amounts of LTB4 and PGE2 
increase dramatically upon induction of an acute inflammatory response, lipoxin A4 (LXA4) is 
released in the late phase in parallel with a sharp reduction of neutrophil trafficking [29]. The 
same study showed that PGE2 induces the lipoxygenase-class switching (from 5-LOX to 15-
LOX activity) in neutrophils leading to reduced synthesis of LTB4 and increased synthesis of 
LXA4 [29].  
An analog of the LXA4, the 15-epi-lipoxin or aspirin-triggered lipoxin has also been shown to 
be synthesized through an alternative pathway after the acetylation of COX-2 by aspirin [30]. 
Acetylation does not completely block the catalytic activity of COX-2 but shifts it from 
endoperoxidase to LOX activity and COX-2 starts transforming arachidonic acid to the 
precursor of aspirin triggered LXA4, 15(R)-HETE. Although the stereochemistry of the 
aspirin triggered LXA4 differs from the naturally produced ones it has the same pro-resolving 
functions [31].  
LXA4 and aspirin triggered LXA4, display a variety of anti-inflammatory and pro-resolving 
actions. They block neutrophil chemotaxis and neutrophil adhesion to and transmigration 
through endothelial monolayers [32,33], increase monocyte migration and non-phlogistic 
phagocytosis of apoptotic neutrophils by macrophages [34]. LXA4 and aspirin triggered LXA4 
are protective in many animal models of acute or chronic inflammation, where they reduce 
neutrophil infiltration, increase survival and decrease the extent of tissue damage (for review 
see [35] ). 
Several further pro-resolving lipid mediators have been since isolated from inflammatory 
fluids taken during resolution of inflammation from animals treated with aspirin. It has been 
shown that the aspirin acetylated COX-2 is able to transform the omega-3 PUFAs 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) to 18-HEPE and 17-HDHA, 
respectively. These precursors are subsequently transformed by LOXes to resolvins and 
protectins. Resolvins of the E series are derived from EPA, while protectins and D series 
resolvins are derived from DHA. Similarly to LXA4, resolvins were shown to be synthetized 
upon cell-cell interaction (Figure 1.2). For example, aspirin treated endothelial cells were 
reported to convert EPA to 18-HEPE, which was be further converted to RvE1 by activated 
neutrophils [36]. RvE1 as well as RvD1 and protectins have been also detected in biological 
fluids of animals and humans not treated with aspirin, suggesting that they have physiological 
functions and can be synthesized without the aspirin intervention on COX-2 [37]. Resolvins 
of the D series and protectins were shown to be synthesized by LOX pathways, E series 
resolvins have been suggested to be synthesized in a pathway involving the cytochrome P-450 
[38].  
 Eicosapentaenoic acid
C20:5
Resolvins
E series
Docosahexanoic acid
C20:6
Resolvins 
D series
Protectins
18-HEPE 17-HDHA
5-LOX 5-LOX
Acetylated
COX
Epoxidation
15-LOXorCP-450 or Acetylated
COX
Figure 1.2: Synthesis of resolvins and protectins 
In vascular endothelial cells, aspirin acetylated COX-2 transforms EPA to 18-HEPE, which is 
taken up by neutrophils, and further converted to E series resolvins by 5-LOX activity. 
Similarly, DHA is converted to 17-HDHA by acetylated COX-2 in endothelial cells, and 
further to D series resolvins by 5-LOX activity or to protectins by epoxidation in neutrophils. 
Alternatively in the absence of aspirin, 18-HEPE and 17-HDHA can be synthetized by CP-450 
or 15-LOX, respectively.  
Resolvin E1 and resolvin D1 have been so far studied most extensively. Similar to LXA4, 
RvE1 and D1 reduce neutrophil infiltration and have been shown to be beneficial in many 
animal models of acute and chronic inflammation having protective function, increasing 
survival rates and reducing tissue damage and loss of function (for review see [39] ). The 
beneficial effects of an elevated dietary intake of omega-3 polyunsaturated fatty acids, 
specifically eicosapentaenoic acid (EPA) and docosahexaenoic (DHA), are widely accepted. 
They have been shown to be protective in conditions associated with chronic inflammation 
like cardiovascular disease, arthritis, Alzheimer’s disease, asthma and peritonitis as well as 
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components of metabolic syndrome [40,41,42,43,44,45]. However, the mechanism of their 
protective action had not been understood. Lipid mediators derived from EPA and DHA with 
their anti-inflammatory and pro-resolving properties are believed to be one of the underlying 
explanations for the beneficial character of omega-3 PUFA [46]. 
1.2 Resolvin E1 
Resolvin E1 (Figure 1.3) is a lipid mediator, which was first isolated during the resolution 
phase of inflammation from mice treated with aspirin and EPA [36]. Given the potent pro-
resolving characteristics of RvE1 similar to the actions of the lipoxins, GPCRs closely related 
to the ALXR were screened for RvE1 stimulated activation. The GPCR ChemR23 was 
identified as the receptor through which Resolvin E1 inhibited TNFα stimulated NF-κB 
activation in ChemR23 transfected HEK cells [47].  
 
 
Figure 1.3: Structure of the lipid mediator Resolvin E1 
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid,  
source www.cyberlipid.org 
1.2.1 Resolvin E1 signaling 
Downstream signaling through ChemR23 
Although the signaling pathway triggered upon RvE1 binding to ChemR23 in different cell 
types remains to be established, one study pinpointed several enzymes that could be involved 
in its signaling in human macrophages. Ohira et. al. showed that RvE1 induced 
phosphorylation of ribosomal S6 protein (rS6) in a ChemR23 dependent manner. This 
phosphorylation was reduced by the inhibitors of ERKs, PI3-K and mTOR kinases indicating 
that these enzymes are involved in the signaling cascade leading to rS6 phosphorylation. In 
addition, inhibiting ERK and mTOR signaling abrogated RvE1 stimulated phagocytosis in 
macrophages leading to the assumption that ERK, mTOR and rS6 phosphorylation are 
necessary for RvE1 stimulated phagocytosis [48].  
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Downstream signaling through alternative receptors 
Next to ChemR23, RvE1 was also shown to bind the leukotriene B4 receptor BLT1 [49]. 
RvE1 increased intracellular calcium mobilization in human neutrophils and blocked LTB4 
mediated calcium release when given prior to LTB4 exposure. In BLT1 transfected cells, 
RvE1 reduced LTB4 dependent NF-κB activation [49]. In a mouse model of peritonitis, RvE1 
reduced the number of infiltrating neutrophils. This effect could not be shown in BLT1 
deficient (-/-) mice indicating that it is BLT1 dependent [49]. In another study, RvE1 
accelerated apoptosis of neutrophils evoked by phagocytosis of microbial particles and 
enhanced NADPH oxidase-derived reactive oxygen species generation and subsequent 
activation of caspase-8 and caspase-3 in a BLT1 dependent manner [50]. Because ChemR23 
has so far not been detected on the surface of neutrophils it is believed that all effects of RvE1 
on neutrophils are BLT1 driven.  
1.2.2 RvE1 in inflammation 
RvE1 showed beneficial pro-resolving effects in various animal models of acute and chronic 
inflammation. In zymosan induced peritonitis, RvE1 increased the infiltration of mononuclear 
cells when given at the same time with the zymosan challenge. When given at the peak of 
inflammation, RvE1 reduced the numbers of infiltrating neutrophils [51]. In a model of acute 
lung inflammation, treatment with RvE1 at the peak of inflammation facilitated resolution by 
reducing neutrophil and increasing monocyte/macrophage numbers in bronachoalveolar 
lavage fluid [50]. In the 2,4,6-trinitrobenzene sulfonic acid induced colitis, a model for 
Crohn’s disease, mice treated with RvE1 had an improved survival rate, lost less weight and 
the colonic mucosa was less affected than in not treated mice [52]. Also in the dextran sulfate 
sodium induced colitis, RvE1 had a beneficial impact on body weight, colon length and the 
state of the colon epithelium [53]. In a rabbit model of periodontitis, topical treatment with 
RvE1 reduced alveolar bone destruction and extremely reduced the neutrophil infiltration 
[54]. Furthermore, RvE1 reduced inflammation in ocular tissues by reducing the number of 
infiltrating macrophages [55]. Another role was recently revealed, when it was shown that 
RvE1 along with RvD1 and LXA4 regulate and reduce pain [56,57,58]. Several synthetic 
analogs of resolvins and lipoxins are currently in clinical trials for ocular, lung, bowel and 
kidney inflammation [38]. 
The above described systemic pro-resolving effects are due to differential signaling of RvE1 
in several cell types. As described above, RvE1´s potent effects on neutrophils are most likely 
solely elicited through the LTB1 receptor as neutrophils do not express ChemR23. In contrast, 
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RvE1 signaling in macrophages and DCs have been shown to be ChemR23 dependent. In 
macrophages, RvE1 increases phagocytosis of microbial particles as well as of apoptotic 
neutrophils in ChemR23 dependent manner [48,59] and thus greatly contributes to the 
clearance of the inflamed area. In dendritic cells isolated after injection of a pathogen extract, 
RvE1 blocks IL-12 secretion [47]. RvE1 was further reported to signal in platelets, where it 
reduced ADP-stimulated aggregation and thromboxane generation in a ChemR23 dependent 
manner. In human intestinal epithelial cells, RvE1 in a ChemR23 dependent manner induced 
the intestinal alkaline phosphatase, which can detoxify gram-negative bacteria by 
dephosphorylation of LPS and thus contribute to the reduction of inflammation [53]. 
1.2.3 RvE1 in obesity 
Although RvE1´s receptor ChemR23 is highly expressed in adipocytes and was shown to play 
a role in adipocyte differentiation and metabolism, RvE1 signaling in adipocytes has not been 
studied. Resolvin E1 and its precursor 18-HEPE have been detected in human subcutaneous 
and perivascular adipose tissue [60]. 18-HEPE was also detected in mouse adipose tissue, 
where it was significantly increased in obese mice. A greater increase was observed in 
genetically caused obesity in leptin deficient ob/ob mice and a milder increase during diet 
induced obesity in wild type (WT) mice. RvE1 itself was detectable in mouse adipose tissue 
only after a n-3 PUFA treatment, which was connected with increased adiponectin in plasma, 
increased transcription of peroxisome proliferator-activated receptor gamma (PPARγ) and 
glucose transporter (GLUT-4) and improved insulin sensitivity [61]. Although another 
member of the resolvin family - RvD1 was shown to reduce inflammation and macrophage 
infiltration in obese fat and skew macrophage polarization in obese fat towards M2 phenotype 
[62,63], similar studies with RvE1 have not been reported. 
However, systemic RvE1 treatment may have a beneficial effect on metabolic syndrome as 
intraperitoneal injection of RvE1 protected against hepatic steatosis in ob/ob mice. It 
decreased numbers of macrophages infiltrated in the liver and induced adiponectin, GLUT-4, 
insulin receptor substrate (IRS-1), and PPARγ expression in the adipose tissue indicating that 
RvE1 could improve insulin sensitivity in obese animals [64]. However, the cellular signaling 
behind these systemic changes was not followed. 
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1.3 Inflammation in obesity  
Obesity is a growing problem world-wide. According to the WHO, obesity has reached 
epidemic proportions globally, with at least 2.8 million people dying each year as a result of 
being overweight or obese. Individuals with BMI ≥ 30 are considered obese, however, 
overweight with a BMI ≥ 25 can already have health damaging effects [65,66]. This is 
because excessive body fat is closely associated with risk factors for diseases such as type 2 
diabetes (T2D), cardiovascular disease and hepatic steatosis [67]. It has been for some time 
recognized that obesity is connected with low level systemic inflammation, which is the 
driving force behind most obesity related disorders [68]. 
1.3.1 Possible triggers of obesity induced inflammation 
The exact reason why inflammation is initiated in adipocytes with increasing fat mass is to 
date unknown. However, there are several hypotheses on the molecular and cellular triggers 
of adipose tissue inflammation. First, nutrient overload can activate pathogen-sensing 
receptors. For example, increased levels of free fatty acids in the circulation can be observed 
in obesity. It has been shown that saturated free fatty acids can trigger TLR-4 signaling and 
initiate inflammatory signaling in adipocytes and macrophages and induce ROS production in 
vascular endothelial cells [69,70]. Further, growing adipose tissue is not enough vascularized 
and adipocytes can be exposed to hypoxic conditions which leads to induction of 
inflammatory gene transcription and to cell damage and cell death [71]. Next, excessive 
nutrient intake leads to perpetuating ER stress of the adipocytes which ultimately leads to 
apoptosis of the cells [72]. The expression levels of genes involved in ER stress have been 
shown to be significantly upregulated in obese mice. The ER stress caused increased 
transcription of the inflammatory cytokines TNFα, IFN-γ, IL-1β and IL-6, and its alleviation 
led to suppression of these cytokines and to improvement of metabolic dysfunction [72].  
1.3.2 Signs and consequences of obesity induced inflammation 
The low systemic inflammation induced by and prevailing during obesity differs in many 
aspects from classical inflammation described above. First, it is initiated within the adipose 
tissue in response to excessive nutrient intake and is driven and sustained by specialized 
metabolic cells such as adipocytes [73]. Second, it is not accompanied by any of the cardinal 
signs of inflammation and it remains on a low level with modest but prevailing increase of 
11 
cytokines. Finally, obesity induced inflammation stays unresolved during the overweight state 
but can be reversed by weight loss [74,75].  
Adipose tissue is not only an energy storage organ and fat depot. It is an active endocrine 
organ secreting mediators and signaling peptides regulating satiety, energy expenditure, 
glucose and lipid metabolism, and inflammation. During obesity, this system gets out of 
balance. In obese adipose tissue, the adipocytes become enlarged [76] and secrete increased 
amounts of TNFα [77], IL-6 and CCL2 [78]. These inflammatory cytokines and chemokines 
secreted by adipocytes attract increased numbers of macrophages into the adipose tissue [79]. 
In fact, crown-like structures of macrophages surrounding adipocytes are a typical feature of 
obese adipose tissue [76]. Infiltrated macrophages scavenge apoptotic adipocytes and are 
thought to contribute to remodeling of the adipose tissue [68]. Also a shift in macrophage 
polarization from M2 to M1 can be observed in obese adipose tissue [80]. As a result, obesity 
is connected with elevated concentration of inflammatory cytokines such as TNFα, IL-6, IL-
1β and CCL2 in the circulation contributed from obese adipocytes and adipose tissue M1 
macrophages [75,81]. These cytokines attract and activate further immune cells and so lead to 
aggravation of the inflammatory status of the tissue. At the same time lower concentrations of 
anti-inflammatory IL-10 and adiponectin can be observed within the adipose tissue caused by 
the phenotype switch in macrophages and by the inflamed nature of the adipocytes [35]. 
Furthermore, recent studies have provided evidence that CD8+ T lymphocytes are present in 
obese adipose tissue and contribute to macrophage recruitment and adipose tissue 
inflammation [82]. 
One of the most common consequences of the obesity induced inflammation is insulin 
resistance. Inflammatory stimuli such as TNFα, secretion of which is increased in obesity, 
decrease insulin signaling in adipocytes and thus decrease their insulin sensitivity and 
subsequently glucose uptake [83]. At the same time, nutrient or inflammatory signals activate 
kinases such as c-jun terminal kinase (JNK) and the inhibitor of κ kinase (IKK), which target 
IRS-1 and inhibit the insulin receptor signaling cascades [81,84]. In addition, these kinases 
activate the transcription factors activator protein-1 (AP-1) and NF-κB, respectively, inducing 
transcription of inflammatory genes including inflammatory cytokines such as TNFα and IL-
1β [68]. This leads to further augmentation of the inflammation. TNFα and IL-1β and 
interferons were also reported to interfere with lipid storage in adipocytes by inducing 
lipolysis [85] and blocking the nuclear receptor PPARγ, which regulates adipogenesis and 
lipid and glucose metabolism in adipocytes [86]. As a consequence of PPARγ 
downregulation, adiponectin expression is reduced. Adiponectin is an important inducer of 
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insulin sensitivity in adipose tissue, liver and skeletal muscle. Moreover, adiponectin 
stimulates secretion of anti-inflammatory cytokines (i.e., IL-10), blocks NF-κB activation, and 
inhibits release of TNFα, IL-6, and inflammatory chemokines from macrophages [87,88]. 
Thus obesity induced inflammation is closely intertwined with insulin insensitivity which 
eventually leads to the development of T2D.  
In addition, obesity and the obesity associated insulin resistance are important independent 
risk factors for cardiovascular diseases [89]. Low systemic inflammation accompanying 
obesity as well as the disrupted lipid and glucose metabolism in obese adipose tissue induce 
and accelerate the progression of atherosclerosis [78].  
1.4 Inflammation in atherosclerosis and coronary artery disease 
Atherosclerosis is a condition, in which fatty streaks are created in the arterial intima and 
develop into atherosclerotic lesions or plaques. These plaques can obstruct the blood flow 
causing arterial stenosis or rupture leading to exposure of prothrombotic material from the 
plaque to blood. Subsequently created thrombus can cause myocardial infarction or ischemic 
stroke and lead to death. Atherosclerosis is the underlying cause of coronary artery disease 
(CAD), the leading cause of death worldwide. Obesity, hypercholesterolemia, high blood 
pressure, smoking and age are all factors involved in the progression of atherosclerosis. 
However, inflammation is an important player in atherosclerosis from the initiation of the 
plaque formation to its regression, or growth and final rupture [3].  
1.4.1 Development of an atherosclerotic plaque 
A detailed understanding of the cellular and molecular events from initiation of 
atherosclerosis to plaque progression and rupture has been acquired using apoE and low 
density lipoprotein (LDL) receptor (-/-) mice, which develop atherosclerosis spontaneously or 
after high fat diet, respectively. Atherogenesis is initiated by the infiltration of LDL particles 
into the intima of the arterial wall [90]. Hypercholesterolemia and sheer stress increased by 
high blood pressure lead to local activation of arterial endothelium [91,92]. As a result, 
endothelial cells express adhesion molecules (e.g. V-CAM1) and leukocyte chemoattractants 
(e.g. CCL2 and CCL5) [93], which enable the adhesion of monocytes and T-cells to the 
endothelium and their subsequent extravasation into the intima. Consequently, LDLR-/- mice 
expressing truncated V-CAM1 show decreased early lesion formation [94]. Once in the 
intima, monocytes differentiate into macrophages and scavenge oxidized LDL particles [95]. 
The center of the plaque becomes filled with such lipid laden macrophages called foams cells 
(Figure 1.4). LDL cholesterol uptake by macrophages leads to their activation and release of 
inflammatory mediators, which attract further monocytes into the lesion and activate the 
present T-cells. The cytokines secreted by activated T-cell then contribute to the inflammation 
in the plaque. For example, IFN-γ, a cytokine secreted by Th1 cells, is present in the human 
plaques and has pathogenic effects, such as enhanced protease and chemokine secretion, 
upregulation of adhesion molecules, induction of pro-inflammatory cytokines, and enhanced 
activation of macrophages and endothelial cells [96]. Unresolved inflammation leads not only 
to propagation of the plaque but can also negatively influence its stability. For example, IFN-γ 
inhibits proliferation of smooth muscle cells, which stabilize the plaque cap [97]. The lack of 
IFN-γ receptor apoE-/- mice leads to inhibition of atherogenesis [98]. In addition, matrix 
metalloproteinases (MMPs) released by activated macrophages and vascular smooth muscle 
cells degrade the collagen in the cap thus compromising its stability and leading to formation 
of so called vulnerable plaque [99].   
 
Figure 1.4: Cellular composition of an atherosclerotic plaque.  
The core of an atherosclerotic plaque contains free lipids and apoptotic cells. These are 
surrounded by immune cells including macrophages, lipid laden foam cells, T-cell and in 
lower numbers B-cells, mast cells and dendritic cell. A fibrous cap consisting of smooth 
muscle cells and collagen fibers stabilizes the plaque. Taken from [90]. 
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1.4.2 Atheroprotective role of anti-inflammatory and pro-resolving mediators 
Lesion progression and its development into a vulnerable plaque is fueled by impaired 
resolution of inflammation within the plaque. There is evidence that anti-inflammatory and 
pro-resolving signaling molecules could stop or even reverse the process. The anti-
inflammatory cytokines IL-10 and TGFβ have been shown to have great atheroprotective 
effects. IL-10 acts on macrophages, where it induces the suppressor of cytokine signaling 
(SOCS3) and inhibits the NF-κB pathway. This leads to reduced secretion of inflammatory 
cytokines and metalloproteinases, and to the suppression of macrophage mediated T-cell 
activation. In addition, IL-10 has been shown to regulate the uptake and efflux of cholesterol 
in macrophages [100]. LDLR-/- mice systemic overexpression of IL-10 as well as 
overexpression in macrophages protected from atherosclerosis [100], while Il-10 deficiency 
exacerbated atherosclerosis [101]. TGFβ suppresses inflammation by modulating T cell 
activation and promotes collagen production thereby stabilizing the plaque [102]. TGFβ 
deficiency in apoE-/- leads to increased infiltration of inflammatory macrophages and Th1 
cells and to reduced collagen content in the plaque [103]. IL-10 and TGFβ are secreted by 
several cell types including Th2 and regulatory T cell (T-reg) and M2 macrophages. Induction 
of T-reg cells by vitamin D3 or by anti-CD3 antibody treatment have been shown to decrease 
atherosclerosis in apoE-/- mice [104,105]. On the other hand, treatment with thioredoxin 
shifted the macrophage phenotype of lesion macrophages toward M2 and was 
atheroprotective in ApoE knock-in mice [106]. T-reg cell activation or re-polarization of 
macrophages toward the M2 state within the plaque could therefore represent a new strategy 
to combat atherosclerosis [103].  
The lipid mediators lipoxins and resolvins have been reported to stimulate resolution of 
inflammation in many animal models of chronic inflammation [33] and there are hints that 
they are also atheroprotective. Positive effects of individual mediators on several cell types 
contained within the plaques have been shown in cell culture. LXA4 reduced inflammatory 
cytokine secretion in macrophages, and CCL2 and P-selectin expression in endothelial cells 
[107]. In addition, LXA4 and RvE1 inhibit vascular smooth muscle cell migration [108]. As 
the synthesis of these lipid mediators increases after aspirin treatment, they might offer an 
additional explanation for beneficial effects of aspirin treatment in atherosclerosis and CAD 
[30,109].  
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1.4.3 Biomarkers of inflammation in atherosclerosis 
Atherosclerotic plaque is not devoid of the influences from the rest of the body and 
inflammation in other organs and tissues (such as the obesity triggered inflammation in 
adipose tissue) can potentiate plaque progression. Likewise, the inflammation within the 
plaque is not isolated but is reflected by elevated inflammatory markers in the circulation. 
Many inflammatory pathways are implicated in atherosclerosis and the products of several of 
them can be measured and used in the assessment of risk for cardiovascular events. Such risk 
assessment helps to identify high-risk individuals, to diagnose the disease conditions and 
make a prognosis.  
C-reactive protein (CRP), is an acute-phase protein secreted by the liver in response to the 
inflammatory cytokines IL-6, TNFα and IL-1β originating at the site of inflammation. Modest 
elevation of CRP can be observed already in preclinical states of atherosclerosis and it is a 
strong independent predictor of cardiovascular events [110]. In addition, other inflammatory 
markers can indicate the state of the disease. Increased levels of the soluble adhesion 
molecules VCAM and ICAM are observed in patients with acute coronary syndromes and 
CAD [111], while MMPs have been reported to be elevated in patients following myocardial 
infarction and have been suggested as marker of unstable plaques [112]. Finally, the balance 
between pro- and anti-inflammatory cytokines has emerged as a major determinant of plaque 
stability. Increased levels of inflammatory cytokines IL-6, IL-1β, IFN-γ and TNFα and 
reduced levels of the anti-inflammatory IL-10, TGFβ and adiponectin have been reported to 
be associated with CAD and myocardial infarction [111].  
1.5 The receptor ChemR23  
1.5.1 ChemR23 gene and transcript 
ChemR23, also named chemokine-like receptor 1 (CMKLR1), is a GPCR specifically binding 
the peptide chemerin and the lipid mediator resolvin E1. It was indentified in late 1990´s as an 
orphan receptor and localized to the region q24.1 of chromosome 12 [113], [114]. ChemR23 
has 7 membrane spanning domains typical for GPCRs from the rhodopsin family. It is most 
closely related to chemoattractant receptors and to the formyl peptide receptors, not, as its 
second name suggests, to the chemokine receptors. It has high homology to the second 
chemerin receptor GPR1 [115], and the receptors for the complement fragments C3a and C5a 
(Figure 1.5).  
 
Figure 1.5: Phylogenetic tree illustrating the structural similarities between 
ChemR23, other receptors for leukocyte chemoattractants and selected chemokine 
receptors.  
Receptors sharing a ligand with ChemR23 are underlined. The tree was created with 
www.phylogeny.fr. 
Similarly to other chemoattractant receptors, the ChemR23 gene constitutes of a single coding 
exon and at least one non-coding exon with a large intron separating the start points of 
transcription and translation [116]. The cDNA sequences of the human ChemR23 deposited in 
GenBank indicate that it is alternatively spliced. The promoter regions and the transcription 
regulation of the different splicing variants in individual cell types have however not been 
studied. The mouse orthologue of ChemR23 named also DEZ was cloned by Methner et al 
[117] and was localized to the mouse chromosome 5 [118]. The genomic region of the mouse 
ChemR23 orthologue has been closely studied. The ChemR23 gene is transcribed from 2 
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alternative promoters in different cell types and is differently spliced. Both identified 
promoters lack the TATA box [118,119].  
1.5.2 ChemR23 expression 
Transcripts of ChemR23 were first detected by Northern Blotting in the placenta, lung, liver 
and hematopoietic tissues such as spleen, lymph nodes and thymus. Because of the receptor’s 
homology to chemoattractant and formylated peptide receptors, and the high expression in 
hematopoietic and lymphoid tissues, ChemR23 was first closely studied in leukocytes. 
ChemR23 is expressed on circulating monocytes and monocytes derived macrophages [114], 
on subsets of NK cells [120], platelets [121], on circulating dendritic cells and on 
plasmacytoid and myeloid dendritic cells within the lymph nodes but not in Langerhans cells 
(dendritic cells resident in the healthy skin) [122]. In leukocytes, ChemR23 was shown to 
constitute a minor co-receptor for a subset of human immunodeficiency viruses [114,123]. 
Later, ChemR23 was shown to be also expressed on other different cell types - adipocytes and 
preadipocytes [124], human endothelial cells [125], joint chondrocytes [126] and skeletal 
muscle cells [127] and vascular smooth muscle cells [108].  
1.5.3 ChemR23 regulation  
To date, little is known about the regulation of ChemR23 during different stages of the 
immune response. Several groups have studied the changes in ChemR23 transcription and 
protein expression in leukocytes in response to inflammatory or anti-inflammatory stimuli. In 
human monocytes, ChemR23 mRNA levels increased after stimulation with the inflammatory 
cytokines TNFα and IFN-γ [47]. In human macrophages and DCs, low concentrations of LPS 
(10 ng/ml) decreased transcription of ChemR23, while higher concentrations (1 ug/ml) 
moderately increased ChemR23 transcripts as compared with untreated cells [114]. In NK 
cells, ChemR23 was strongly downregulated after long-term (4-6 days) stimulation with IL-2 
and IL-15 - cytokines responsible for the activation of NK cells in terms of cytotoxicity and 
cytokine production [120]. This would suggest that NK cells express ChemR23 only during 
the early phase of migration toward the inflamed tissue. In endothelial cells, ChemR23 is 
upregulated by inflammatory cytokines (IL-1β, TNFα, IL-6) [125]. Overall, it seems that 
ChemR23 is upregulated by inflammatory stimuli, which would hint to its function during the 
early stages of inflammation. 
In mice, ChemR23 was detected on monocytes, macrophages and DC progenitors but not on 
most DCs. In mouse macrophages, ChemR23 was downregulated by inflammatory stimuli 
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such as TLR ligands (LPS, CpG) and inflammatory cytokines, and upregulated by TGFβ 
[128]. In another study, ChemR23 was downregulated in peritoneal exudate cells after an 
overnight treatment with IFN-γ and LPS but not with IL-4 or IFN-γ alone [129]. The authors 
of these studies suggest that ChemR23 has an anti-inflammatory role. It remains unclear why 
the regulation differs in mice and human and whether it is possible to ascribe to ChemR23 a 
clear inflammatory or anti-inflammatory function. 
1.5.4 ChemR23 deficiency in mouse models 
Several ChemR23-/- mouse models have been reported. Although ChemR23 is present on the 
surface of many different cell types and was shown to have a role in leukocyte recruitment, 
adipogenesis and β-cell function as is in detail described below, ChemR23-/- mice exhibit no 
obvious difference in phenotype to WT mice. Under normal conditions, ChemR23-/- mice are 
generally healthy, fertile and have no immune abnormalities [130,131,132,133,134]. The lack 
of ChemR23 only becomes apparent in experimental models of acute or chronic inflammation 
and upon metabolic challenges. ChemR23-/- mice exhibited increased accumulation of 
neutrophils and macrophages in lungs after LPS-induced lung insury [133]. However, 
decreased accumulation of macrophages and smaller inflammatory lesions in the central 
nervous system was observed in a mouse model of multiple sclerosis [130]. In addition, 
reduced food consumption, body mass and adiposity was reposted in ChemR23 -/- deficient 
mice by Ernst et. al.. Lack of ChemR23 was also associated with lower blood glucose, insulin, 
leptin and adiponectin levels, and reduced glucose tolerance in diet induced obesity [134]. 
1.6 Chemerin 
Chemerin was identified as a ligand of ChemR23 by testing fractions of human inflammatory 
fluids [135], and by screening of a hemofiltrate peptide library [136] for biological activity 
specific for ChemR23 expressing cells. The active molecule was subsequently characterized 
as the product of the human Tig-2 (tazarotene-induced 2) gene previously described as a 
retinoid-responsive gene in psoriatic skin lesions [137].  
1.6.1 Chemerin expression and isoforms 
Chemerin is synthesized as a 163 amino acid (AA) long pre-proprotein, which is cleaved on 
the N-terminus in the cell and secreted as a 143 AA long inactive prochemerin (Chem 21-163) 
[135,136]. Prochemerin can be activated through the cleavage of its C-terminus by proteases 
of the coagulation and fibrinolytic cascades, and by proteases released from activated 
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neutrophils or mature adipocytes [138,139]. Active chemerin isoforms have been detected in 
inflammatory and other biological fluids (Table 1.1) and in minor quantities in plasma. The 
inactive prochemerin was found to circulate in blood [140].  
Table 1.1: Biological sources of identified chemerin isoforms 
Ascites [135] Chem 21-157 
Hemofiltrate [136] Chem 21-154 
Cerebrospinal fluid [141,142] Chem 21-158 
Plasma [139,140,141,142] Chem 21-155, -157, -158, -163 
Synovial fluid [142] Chem 21-158 
 
Chemerin is mainly expressed by the liver, white adipose tissue, and placenta [124,143] and 
to a lesser extend by many other tissues such as lungs, brown adipose tissue, heart, kidney, 
skeletal muscle, pancreas [144] and platelets [145]. Liver and white adipose tissue are 
believed to be the main source of circulating chemerin [146].  
The degree of chemerin activity depends on the exact cleavage by each of its processing 
enzymes [139]. Some proteases were found to cleave chemerin at more than one site and it 
was also suggested that some chemerin isoforms can be consecutively cleaved by different 
proteases thereby modulating the degree of their activity. Chemerin activation and function is 
believed to be regulated specifically in different tissues and at different time-points depending 
on the expression and activity of chemerin processing enzymes. The activity of different 
chemerin isoform has been studied in vitro by several groups. Figure 1.6 gives an overview of 
chemerin processing enzymes, and of the resulting chemerin isoforms and their activity.  
 Figure 1.6: Overview of chemerin processing and activity of individual isoforms 
The inactive prochemerin (AAs 20 – 163 of pre-prochemerin) can be cleaved by different 
proteases (white boxes) leading to isoforms of different lengths and varying activities. 
For example, cleavage of 6 C-terminal AAs by leukocyte elastases or sequential cleavage 
by plasmin and carboxypeptidase N or B results in Chem-157 with the highest activity. 
Subsequent cleavage of 3 AAs by mast cell chymase leads to inactivation. Elastase and 
tryptase have also been reported to generate Chem-155, which has no activity itself but is 
capable of competing with more potent isoforms thus blunting their effect.  
Taken from [146] 
In addition, several studies have shown that synthetic chemerin-derived peptides consisting of 
the C-terminal 9-15 AAs alone have considerable activity. On the other hand, fragments of 
the mid- and N-terminal parts of the sequence do not seem to be essential for the degree for 
chemerin activity [131,133,147,148]. The C-terminal nonapeptide is the shortest chemerin 
derived peptide retaining chemerin specific activity [133,147]. Its sequence is highly 
conserved in all mammalian species  and it has a high affinity to ChemR23 [133]. It is used in 
in vitro studies instead of full length chemerin, because the production of the recombinant 
chemerin proved to be a tedious process [147]. 
1.6.2 Chemerin signaling 
Downstream signaling through ChemR23 
The exact downstream signaling pathways triggered upon chemerin binding to its receptor in 
different cell types still have to be elucidated. In early studies, chemerin treatment was shown 
to trigger intracellular calcium release, phosphorylation of the p42 (ERK1) and p44 (ERK2) 
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MAP kinases and the inhibition of cAMP accumulation in ChemR23 transfected CHO-K1 
cells [135]. Chemerin stimulation also lead to ERK1/2 phosphorylation in human endothelial 
cells, adipocytes, chondrocytes and fibroblast-like synoviocytes [124,125,126,149]. In human 
endothelial cells and chondrocytes, and in mouse macrophages, chemerin was also shown to 
induce the p38 MAP kinase and Akt signaling [129,149].  
Downstream signaling through alternative receptors 
In addition to ChemR23, chemerin binds two other GPCRs – the chemokine (CC motif) 
receptor-like 2 (CCRL2) and the GPR1. 
CCRL2 is expressed on endothelial cells [150], adipocytes [151] and in most hematopoietic 
cell types [152]. Chemerin binding to CCRL2 does not trigger ligand internalization or any 
signaling inside the cell. Instead, CCLR2 binding accumulates chemerin on the cells surface 
and thus increases local chemerin concentration and availability [153].  
GPR1 was reported to bind chemerin with comparable affinity to ChemR23 [115]. In pigs, the 
GPR1 orthologue was shown to be expressed mainly in liver, spleen, kidney and adipose 
tissue [154]. There is however nothing known about the function and signaling of this 
receptor. 
1.6.3 Chemerin in inflammation 
Chemerin was initially shown to act as a chemoattractant of ChemR23 expressing DCs, 
macrophages [135] and NK cells [120]. Active chemerin, capable of attracting ChemR23 
expressing DCs ex vivo, was detected in psoriatic skin lesions [155]. Chemerin is found to be 
upregulated within inflamed tissues such as psoriatic skin and lupus lesions and in arthritis 
[122,135,149], and chemerin and infiltrating ChemR23 positive DCs or NK cells were also 
detected in oral lichen planus biopsies [120], kidney biopsies from patients with lupus 
nephritis [156] and in skin lupus lesions [122]. It is therefore believed that chemerin 
contributes to the recruitment of ChemR23 expressing leukocytes to these inflamed tissues.  
In some studies, chemerin was additionally reported to have a direct pro-inflammatory role. It 
enhanced the secretion of pro-inflammatory cytokines such as IL-6, IL-8, TNFα, CCL2 and 
IL-1β [126,149] in cultured human chondrocytes and fibroblast-like synoviocytes in-vitro. 
These findings support the notion that chemerin may have pro-inflammatory properties. 
Conversely, inflammatory cytokines increased chemerin secretion in some cell types: TNFα 
increased total and bio-active chemerin secretion in human and murine adipocytes, and in 
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human intestinal epithelial cells and fibroblast-like synoviocytes [149,157,158]. IL-1β 
increased total chemerin secretion in adipocytes [159].  
Elevated chemerin levels in the circulation are associated with several inflammatory diseases. 
Significantly elevated plasma chemerin levels were reported in patients with Crohn’s disease 
and ulcerative colitis [160], chronic kidney disease [161] and chronic pancreatitis [162]. 
Plasma chemerin levels are positively correlated with CRP, the pro-inflammatory adipokines 
leptin and resistin [143,163,164,165], and with the levels of the inflammatory cytokines TNFα 
and IL-6 [165], and negatively correlated with the anti-inflammatory adipokine adiponectin 
[166,167]. In rheumatoid arthritis patients, anti-TNF therapy decreased circulating chemerin 
levels together with decreasing IL-6 levels and disease activity parameters [168]. 
However, it is dificult to interpret these increased chemerin levels in terms of possible 
functionality of chemerin in these diseases. Although the ratio of active to non-active 
chemerin would be decisive for its final signaling, most studies measure total chemerin level 
not distinguishing between individual isoforms. Therefore, the significance of elevated 
chemerin levels in circulation and in inflammatory fluids, and their impact on the disease are 
uncertain. For example in renal epithelial cells TNFα treatment in vitro significantly 
downregulated chemerin secretion. However, the supernatants of the TNFα treated cells 
attracted plasmacytoid DCs, in a ChemR23 dependent manner, more potently than 
supernatants from untreated cells [156]. This suggests that although TNFα reduces total 
chemerin secretion in renal epithelial cells, it at the same time promotes pro-chemerin 
cleavage and activation.  
Animal models of inflammation 
Controversly, in animal models of acute and chronic inflammation, chemerin was reported to 
have both pro and anti-inflammatory actions. In a mouse model of LPS-induced acute lung 
inflammation, chemerin reduced neutrophil infiltration and dampened inflammatory cytokine 
increase in bronchoalveolar lavage fluid [133] in a ChemR23 dependent manner. Chemerin 
treatment prior to M1 polarization with LPS and IFN-γ, inhibited inflammatory cytokine 
secretion (TNFα, IL-1β, IL-6 and IL-12) and induced the transcription of the anti-
inflammatory TGFβ and IL-10 in mouse peritoneal macrophages. The described effects were 
completely ChemR23 dependent and were not seen in macrophages isolated from ChemR23-/- 
mice [131]. However, when an independent group repeated the experiment, chemerin pre-
stimulation did not significantly affect the cytokine production in neither murine nor human 
LPS/IFN-γ stimulated macrophages [169]. Some stable chemerin derived peptides also proved 
to be anti-inflammatory. For example, the administration of a 15 AA long peptide (C15) 
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derived from chemerin´s C terminus prior to zymosan challenge protected mice against 
zymosan-induced peritonitis. The peptide C15 reduced the numbers of infiltrating monocytes 
and neutrophils and diminished peritoneal expression of inflammatory cytokines. In contrast, 
C15 could not suppress zymosan induced leukocyte recruitment in ChemR23-/- mice 
indicating that these effects were ChemR23 dependent [131]. C15 was also reported to 
increase murine macrophage phagocytosis of microbial particles and apoptotic cells in vitro 
and to enhance the clearance of microbial particles and apoptotic neutrophils in zymosan-
induced peritonitis [148].  
Some of the above described anti-inflammatory effects of chemerin are most probably due to 
chemerin´s action on non-leukocytic cells, such as epithelial or endothelial cells, where there 
is indication that chemerin could induce rescue pathways and reduce leukocyte cell 
adherence. In epithelial cells, chemerin increased the intestinal alkaline phosphatase 
expression in vitro leading to detoxification of E. coli cells [53] and in human vascular 
endothelial cells, chemerin attenuated TNFα-induced VCAM-1 expression, leading to 
decreased monocyte adhesion to the endothelial cells [170].  
On the other hand, chemerin signaling seems to be required for the initiation of inflammation 
by attracting leukocytes. For example, ChemR23-/- mice develop milder experimental 
autoimmune encephalomyelitis likely due to lower macrophage counts in the lesions [130]. 
Inflammation caused by chronic cigarette smoke exposure lead to increased chemerin release 
in the lung epithelium of mice. This inflammation was attenuated in ChemR23-/- mice through 
reduced recruitment of inflammatory neutrophils and monocytes [132]. When administered to 
murine macrophages, chemerin promoted their adhesion to the extracellular matrix protein 
fibronectin and to the adhesion molecule VCAM-1, supporting a role in the recruitment and 
retention of leukocytes at sites of infiltration [129].  
In summary, chemerin was reported to trigger both inflammatory and anti-inflammatory 
signals depending on the cell type it acts on and on the proteolytic cleavage it undergoes. It 
remains to be established in which moment of inflammation chemerin is most essential – 
initiation or resolution. 
1.6.4 Chemerin in adipose tissue and obesity 
In 2007 chemerin was identified as an adipokine. Chemerin secretion is induced during 
differentiation of pre-adipocytes to mature adipocytes and chemerin signaling through 
ChemR23 on preadipocytes was shown to be essential for adipocyte differentiation [124,143]. 
Chemerin or ChemR23 shRNA knockdown in preadipocytes block their differentiation and 
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affect expression of proteins involved in glucose and lipid metabolism such as the glucose 
transporter GLUT4, hormone sensitive lipase and the insulin receptor [124]. Chemerin 
signaling was also shown to be essential during the early clonal expansion phase of adipocyte 
differentiation [171]. Consistent with this, a loss of ChemR23 function in mice is associated 
with reduced body mass due to reduced body fat, and with  resistance to diet-induced obesity 
[134] suggesting that chemerin-ChemR23 signaling is essential for adipogenesis in vivo. 
Chemerin expression in preadipocytes is positively regulated by PPARγ [171] – an important 
regulator of adipogenesis and adipocyte metabolism.  
In both man and mice, chemerin plasma levels are elevated in obese individuals. Chemerin 
levels are correlated with BMI and the waist-hip ratio in humans [143,172] and decrease after 
a bariatric surgery in parallel to the decrease of body fat mass [166]. This elevated chemerin is 
believed to originate from adipose tissue [173]. This notion is supported by reports that 
adipose tissue explants from obese individuals secrete significantly more chemerin than those 
isolated from lean individuals, and this secretion correlates with increased BMI, waist to hip 
ratio and fat cell volume [127]. Obesity is commonly associated with low systemic 
inflammation and chemerin has been suggested to be a link between obesity and inflammation 
[146]. Considering chemerin´s function as a chemoattractant of macrophages, increased 
chemerin production in the obese adipose tissue [127] might be responsible for the observed 
excessive infiltration of macrophages [79]. In line with this, chemerin concentrations in obese 
patients positively correlate with the amount of macrophages in the omental adipose tissue 
[172] and mice lacking chemerin have less macrophages infiltrating into the adipose tissue 
[144]. Furthermore, macrophage secreted inflammatory cytokines TNFα and IL-1β are 
positive regulators of chemerin secretion by adipocytes [157,159] possibly creating a vicious 
cycle of activation.  
Elevated chemerin levels have been observed in individuals with the metabolic syndrome and 
are correlated with its markers such as low HDL cholesterol, and high blood pressure 
[143,163]. In mouse models, chemerin was reported to affect glucose tolerance and insulin 
secretion [134,174]. Therefore, it was surmised that chronically elevated chemerin levels in 
obesity might exacerbate already present glucose metabolism impairments and further 
contribute to the development of metabolic syndrome [173]. 
1.6.5 Chemerin in atherosclerosis 
As inflammation and obesity are important risk factors for coronary artery disease, chemerin 
could play a role in the pathology of this disease. Although chemerin levels are associated 
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with several risk factors for CAD such as chronic inflammation and obesity, systemic 
overexpression of human chemerin in mice lacking the LDL-receptor did not affect the extent 
of atherosclerosis investigated by en face analysis of the entire aorta [175]. In humans, several 
small case-control studies have been carried out showing contentious results for the 
association of chemerin plasma levels with CAD. While 2 studies in Asians showed an 
association of plasma chemerin levels with atherosclerotic diseases [176,177] a third study in 
Caucasians showed no association [165].  
1.6.6 Chemerin and RvE1 binding to ChemR23  
Curiously, the two ligands of ChemR23, chemerin and RvE1 have been shown to elicit 
different responses upon binding the receptor in ChemR23. In a study by Arita et. al., RvE1 
and a 12-AA fragment derived from chemerin competed for ChemR23 binding suggesting an 
identical binding site. However, in ChemR23 transfected HEK cells, the chemerin peptide 
increased extracellular acidification rates, while RvE1 had no effect. In contrast, both the 
chemerin peptide and RvE1 inhibited TNFα induced NF-κB luciferase activity. The authors 
concluded that RvE1 and chemerin use different signaling pathways through ChemR23 [47]. 
Other studies suggest that some chemerin peptides have the same effects as RvE1. For 
example, in human intestinal epithelial cells, both chemerin and RvE1 induced the intestinal 
alkaline phosphatase in a ChemR23 dependent manner [53]. This would argue for an identical 
pathway triggered by both ligands. However, the exact downstream signaling was not studied. 
The C15 chemerin peptide was reported to induce macrophage phagocytosis in murine cells in 
ChemR23 dependent manner, an effect also ascribed to RvE1 [148]. The effect could be 
blunted by an inhibitor of Syk tyrosine kinase in macrophages, which is required for lysosome 
phagosome fusion [148]. On the other hand, RvE1 stimulated macrophage phagocytosis 
engaged the Akt, ERK and mTOR kinases [178]. It is therefore likely that RvE1 and different 
chemerin peptides trigger different signaling pathways in different cell types. In addition, 
even within one cell type, binding of these ligands to ChemR23 could lead to initiation of 
different signaling outcomes. In GPCRs, ligand binding leads to phosphorylation, which 
mediates uncoupling from the G-protein but can also drive G-protein independent signaling 
[179,180]. It has been recently shown that the site of this phosphorylation is cell type and 
ligand specific, and that by adopting a specific phosphorylation profile the receptor could 
initiate a particular pathway [181] .  
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1.7 Significance of studying ChemR23  
The prevalence of obesity is growing world-wide. According to the WHO more than 1.4 
billion adults are obese globally and the number of children who are overweight is rapidly 
growing. Obesity is associated with secondary disorders such as cardiovascular disease and 
type-2 diabetes, which are accelerated by impaired cellular lipid and glucose metabolism, and 
by chronic low grade inflammation prevalent in obesity [68]. ChemR23-chemerin signaling is 
implicated in inflammation as well as in adipogenesis and adipocyte metabolism [173]. The 
ChemR23-chemerin axis may therefore represent an important link between inflammation, 
obesity and obesity related disorders.  
The second ligand for ChemR23 is the lipid mediator RvE1, a metabolite of the omega-3 fatty 
acid EPA. RvE1 is one of the mediators thought to mediate the protective effects of dietary 
EPA [46]. Although RvE1 has established pro-resolving properties in acute inflammation 
models, its action in different stages of inflammation and its role in chronic inflammation is 
largely unknown.  
Better understanding of the regulation of ChemR23 expression in different subsets of 
monocytes and macrophages will help to pinpoint the phase of inflammation, in which 
ChemR23-RvE1 and ChemR23-chemerin signaling is relevant. In addition, investigating 
polymorphisms in ChemR23 for an association with CAD, may implicate these two signaling 
pathways as players in atherogenesis and may identify ChemR23 as a potential new drug 
target.  
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2.1.1 Abstract 
ChemR23 is a G-protein coupled receptor expressed on monocytes, macrophages, dendritic 
and natural killer cells. Two ligands signal through ChemR23 – the peptide chemerin and the 
eicosapentaenoic acid derived lipid mediator resolvin E1 (RvE1). Chemerin acts as a 
chemoattractant for ChemR23 expressing leukocytes, while RvE1 promotes resolution of 
inflammation by induction of macrophage phagocytosis of microbial particles and apoptotic 
neutrophils. Although ChemR23 mediated signaling plays a role in mononuclear cell 
immigration to inflamed tissue as well as in the resolution of inflammation, its regulation in 
different polarization states of macrophages is largely unknown. We analyzed the expression 
and function of ChemR23 in monocytes and resting and differently activated human primary 
macrophages. Using 5´ RACE, we identified 3 transcription start sites and several splice 
variants of ChemR23 in both monocytes and macrophages. While the promoters P1 and P3 
are used equally in unpolarized macrophages, stimulation with LPS or IFN-γ leads to 
increased transcription from P3 in inflammatory M1 macrophages. Such ChemR23 expressing 
M1 macrophages are chemotactic to chemerin and increase IL-10 transcription in response to 
RvE1 stimulation. In contrast ChemR23 is not expressed on M2 macrophages, which are also 
not responsive to chemerin. These results show that ChemR23 is tightly regulated in response 
to inflammatory and anti-inflammatory stimuli. The high expression of ChemR23 in naive 
and M1 macrophages supports the role of ChemR23 in the attraction of macrophages to 
inflamed tissue by chemerin and in the initiation of resolution of inflammation through RvE1 
signaling in human macrophages. In contrast, the role of ChemR23 mediated signaling is 
limited in M2 macrophages. 
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2.1.2 Introduction 
Macrophages are key players in innate immunity with an essential role in inflammatory 
processes [1]. Due to their phenotype diversity and plasticity, macrophages participate in all 
stages of inflammation from pathogen recognition to pathogen elimination, and finally to the 
resolution of inflammation [2]. The phenotype of macrophages changes in response to stimuli 
from the environment. Upon stimulation with the Th1 cytokine IFN-γ or TLR-4 ligands, 
macrophages undergo classical M1 activation resulting in high secretion of inflammatory 
cytokines such as TNFα and IL-1β, and strong microbicidal activity mediated by reactive 
oxygen and nitrogen species [3]. In contrast, the Th2 cytokines IL-4 and IL-13 lead to 
alternative M2 activation of macrophages. These macrophages are characterized by high 
secretion of anti-inflammatory IL-10 and IL-1RA, and high expression of the mannose and 
galactose receptors [4]. The M1 phenotype is associated with initiating and progressing 
inflammation, while M2 macrophages are implicated in tissue repair, wound healing and 
parasite infections [3]. In addition, it was shown that macrophages can to some extend switch 
from one activation state to the other [5,6] and intermediate phenotypes have been identified 
in specific stages of the immune response such as resolution of inflammation [7].  
ChemR23, also known as the Chemokine-like Receptor 1 (CMKLR1), is a G-protein coupled 
receptor expressed on monocytes and macrophages, dendritic [8] and natural killer cells [9] as 
well as on adipocytes [10] and endothelial cells [11]. It binds two ligands - the peptide 
chemerin [12], and the eicosapentaenoic acid (EPA) derived lipid resolvin E1 (RvE1) [13]. 
Chemerin is present in high amounts in inflammatory fluids [14], was shown to attract 
ChemR23 expressing leukocytes [12,15], and to promote adhesion of macrophages to 
extracellular matrix proteins [16]. In addition, chemerin was recently discovered to be an 
adipokine [10]. Secreted by mature adipocytes, it stimulates preadipocytes to differentiation. 
Elevated serum levels of chemerin have been associated with chronic inflammatory diseases 
[17] [18], the metabolic syndrome and obesity [19]. There is indication that high chemerin 
production in obese adipose tissue [20] might contribute to the increased infiltration of 
macrophages observed in obese adipose tissue leading to low level inflammation [21].  
The second ligand of ChemR23, RvE1, promotes resolution of inflammation in animal 
models of acute and chronic inflammation [22]. On the cellular level, RvE1 blocks TNF-α 
induced NF-κB signaling [13] and enhances phagocytosis of bacterial particles and apoptotic 
neutrophils by human macrophages in a ChemR23 dependent manner [23]. RvE1 is 
postulated to be one of the mediators of the beneficial effects of dietary EPA, which is 
thought to have protective function in conditions associated with chronic inflammation [24].  
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The above described findings indicate that the receptor ChemR23 plays a role during 
monocyte/macrophage recruitment to the inflamed tissue as well as during the resolution of 
inflammation. With the aim to better understand which macrophage phenotype responds to 
signals triggered through ChemR23, we analyzed the expression and function of ChemR23 in 
resting and differently activated human primary macrophages. We show that ChemR23 is 
expressed in monocytes and macrophages and is upregulated in M1 macrophages, which are 
chemotactic to chemerin and increase IL-10 transcription in response to RvE1 stimulation. In 
contrast, M2 macrophages do not express the receptor. We further show that ChemR23 is 
transcribed from 2 promoters in monocytes and macrophages. While promoters P1 and P3 are 
used equally in unpolarized macrophages, the increased transcription in inflammatory M1 
macrophages is driven from promoter P3.  
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2.1.3 Materials and Methods 
Materials 
The recombinant human cytokines IL-13, IL-1β, TNF-α, TGF-β, and IFN-γ; the TLR-4 ligand 
LPS and the TLR3 ligand poly I:C were purchased from Sigma Aldrich (Buchs, Switzerland). 
IL-4 and IL-6 were purchased from R&D Systems Europe (Abingdon, U.K.). The TLR9 
ligand, CpG, was synthesized by Microsynth (Balgach, Switzerland). The TLR7 and 8 
synthetic ligands 3M001 and 3M002 were purchased from 3M Pharmaceuticals (St. Paul, 
Minnesota, USA). Chemerin (149-157) was purchased from AnaSpec, Inc. (San Jose, USA). 
Chemerin Receptor 23, anti-human, monoclonal antibody (ChemR23 Ab) and isotype IgG3 
were purchased from R&D Systems (Minneapolis, USA). PE-labeled anti-human CD80, 
monoclonal FITC-labeled anti-human CD206 Ab and the IgG1K isotype control were 
purchased from BD Biosciences (San Jose, California USA). 
Primary cell purification and cell culture 
White blood cells from healthy volunteers were isolated as described previously [25] from 
buffy coat (Blutspendezentrum, Zurich, Switzerland) using Histopaque-1077 (Sigma-Aldrich) 
gradient centrifugation. Briefly, monocytes were purified by capture with anti-CD14 Abs 
coupled to MACS Microbeads (MiltenyiBiotec, Bergisch Gladbach, Germany) and let 
differentiate into macrophages for 7 days at 37°C and 5% CO2 in RPMI 1640 (Sigma-
Aldrich) supplemented with 5% Fetal Calf Serum  (Bioconcept, Allschwil, Switzerland), 5% 
human AB serum (Sigma-Aldrich) and 1% penicillin/streptomycin (Invitrogen, Zug, 
Switzerland).  
Human THP-1 monocytes were cultured in RPMI1640 (Sigma-Aldrich) supplemented with 
10% FCS (Bioconcept), 20 mM glutamine (Invitrogen), at 37°C and 5% CO2. For 
differentiation into macrophages, the THP-1 cells were stimulated for 48 hours with phorbol 
12-myristate 13-acetate (PMA) (Sigma-Aldrich). 
RNA isolation and RT reaction for real-time PCR 
Total RNA from primary monocytes and macrophages was isolated using the Rneasy mini kit 
from Qiagen AG (Hombrechtikon, Switzerland). cDNA was prepared by RT reaction from 
1μg total RNA using the Superscript III reverse transcriptase (Invitrogen). 
Relative quantification of ChemR23 expression levels 
ChemR23 expression levels were quantified by real-time PCR using the SYBR Green master 
mix kit (Roche Diagnostics, Rotkreuz, Switzerland) on the Light Cycler 480 (Roche 
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Diagnostics). The reactions were performed under following conditions: preheating 10 min at 
95°C followed by 45 cycles of denaturation 5 sec at 95°C, annealing 10 sec at 60°C and 
extension 6 sec at 72°C. Relative gene expression was normalized to GAPHD. Primers are 
listed in the Supplementary table 2.1. Data was analyzed with Light Cycler 480 software 
(Roche Diagnostics). 
Rapid amplification of cDNA ends 
Total RNA was extracted from primary monocytes and macrophages as described above. 
5´rapid amplification of cDNA ends (RACE) was performed using the RLM-RACE Kit 
(Ambion, Rotkreuz, Switzerland) according to the manufacturer’s instructions. 3 nested PCR 
reactions were performed using the kit’s outer and inner adaptor forward primers and 
ChemR23 specific reverse primers. Primer sequences are listed in Supplementary table 2.2. 
The PCR products were separated on a 2% agarose gel and the corresponding bands were 
extracted from the gel and sequenced. 
Analysis of splicing variants 
Novel exons detected by the RACE were verified by PCR using exon 1, 3 and 4 specific 
primers in combination with the RACE inner reverse primers. All primer sequences are listed 
in the Supplementary table 2.3. PCR products were separated on 2% agarose gel by 
electrophoresis, extracted from the gel and sequenced.  
Generation of promoter constructs 
Promoter constructs were amplified by PCR with primers containing the XhoI, and HindIII 
restriction sites – in forward and reverse primers, respectively (for sequence see 
Supplementary table 2.4). PCR products were TA subcloned into the pCRII vector 
(Invitrogen) and the promoter constructs were cut out using XhoI and HindIII restriction 
enzymes from Fermentas GmbH (St. Leon-Rot, Deutschland). Constructs were further 
subcloned into the promoterless vector pGL4.17 from (Promega, Madison, WI , USA) 
upstream of the firefly luciferase gene. All constructs were sequenced. 
Transcription assays 
10 µg construct, and 0.25 µg internal control phRL-SV40 (Promega) were transfected by 
electroporation into 6x106 THP-1 cells. Electroporation was done under the following 
conditions: 200 V, 950 µF capacitance, and ∞ resistance. After electroporation cells were 
seeded in RPMI 1640 with 10% FCS and 20 mM glutamine. After 2 h, cells were stimulated 
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with PMA for 48 house to differentiate into macrophages. THP-1 macrophages were then 
washed with PBS, lysed in 500 µl passive lysis buffer, and 20 µl of the lysate was used for 
dual luciferase reporter assays (Promega). The luciferase and renilla activities were measured 
on the luminometer Lumat LB-9507 (Berthold Technologies, Regensdorf, Switzerland). All 
experiments were done three times in triplicate. 
FACS analysis 
APC-labeled anti-human ChemR23Ab with the isotype control IgG3, and a monoclonal PE-
labeled anti-human CD80 and a monoclonal FITC-labeled anti-human CD206 with the IgG1K 
isotype control  were used for the FACS analysis. Briefly, cells were resuspended in PBS 
containing 2.5% FCS, and after addition of 10 µl Ab or 4 µl isotype control incubated in the 
dark for 30 min at 4°C before analysis on a FACS Calibur analyzer (BD Biosciences, San 
Jose, USA).  
Chemotaxis assay 
A total of 105 macrophages were placed on a 96-wellmembrane (5.7-mm diameter, 5-μm pore 
size; ChemoTX from NeuroProbe, Gaithersburg, MD) in RPMI 1640 containing 0.1% BSA 
(Sigma-Aldrich). The cells were allowed to migrate toward 10 nM chemerin for 60 min. 
Migrated cells were fixed (2% paraformaldehyde) and stained with DAPI (Sigma-Aldrich), 
and migration was quantified as the total pixel count of DAPI-stained nuclei under the 
fluorescence microscope (two photos per membrane and three replicate wells per treatment). 
Migration indices were calculated over control values. 
IL-10 ELISA 
IL-10 concentrations in supernatants of human macrophages were measured using 
commercially available human IL-10 ELISA (BioLegend, San Diego, USA) according to the 
manufacturer’s instructions. 
Statistical analysis 
Statistical analysis was performed with Graph Pad Prism 4.03. The levels of ChemR23 
mRNA and the activities of the different ChemR23 promoters in the luciferase assays were 
compared using a two-sided t-test. A two-sided p < 0.05 was considered significant.  
2.1.4 Results 
ChemR23 expression is upregulated during monocyte differentiation to macrophages, and 
regulated by cytokines and TLR ligands in macrophages 
Human primary monocytes transcribe and express ChemR23 on their surface (Figure 2.1A 
and B). We quantified ChemR23 mRNA levels during 7 days differentiation of monocytes to 
macrophages. ChemR23 mRNA levels gradually increased from day 1 to day 3 and then 
remained on the same high level (Figure 2.1A). ChemR23 protein expression also 
significantly increased after monocyte differentiation to macrophages. (Figure 2.1B and C).  
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Figure 2.1: ChemR23 expression on monocytes and macrophages 
A. Relative mRNA expression of ChemR23 during the 7 days differentiation of monocytes to 
macrophages. The values were normalized for GAPDH mRNA. Bars indicate the mean of 3 
independent experiments as fold induction of control. *p<0.05, **p<0.01. B. ChemR23 
protein expression on monocytes C. ChemR23 protein expression on macrophages. 
Autofluorescence of the cells is shown in light grey, the isotype control in grey and cells 
labeled with ChemR23 Ab in black. Representative graphs of at least 3 independent 
experiments are shown. 
To asses the expression of ChemR23 in macrophages after activation, we stimulated 
macrophages with cytokines and TLR ligands. ChemR23 transcription and protein expression 
was downregulated by IL-13 and IL-4 (Figure 2.2A, B and C) - cytokines leading to the M2 
phenotype, and by stimulation with the synthetic TLR8 ligand 3M002. On the other hand, 
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ChemR23 transcription was upregulated by the TLR-4 ligand LPS and by the 
proinflammatory IFN-γ - stimuli responsible for induction of the M1 phenotype. LPS 
stimulation also increased ChemR23 protein expression (Figure 2.2D), while IFN-γ and 
3M002 did not significantly change the protein levels (data not shown). Stimulation with IL-
3, IL-8, MCP1, TNFα, TGFβ, and IL-6 and the TLR ligands CpG, 3M001 and poly I:C did 
not significantly affect ChemR23 transcription (Figure 2.2A). In a chemotaxis assay we show 
that these changes on the mRNA and protein level are reflected in functionality. Naive 
(unstimulated) as well as LPS stimulated M1 macrophages actively migrate toward chemerin. 
However, IL-4 and IL-13 stimulated M2 macrophages only show unspecific migration and are 
not attracted by chemerin (Figure 2.2E). These results indicate that alternatively activated M2 
macrophages do not express functional ChemR23 and thus cannot migrate towards chemerin.  
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Figure 2.2: ChemR23 expression and function in macrophages in response to 
inflammatory and anti-inflammatory stimuli 
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A. Relative mRNA expression of ChemR23 after stimulation of human macrophages with 
different stimuli for 24 hours (IL-4 10ng/ml, IL-13 10ng/ml, TGF-β 1ng/ml, IL-1β 1ng/ml, IL-
6 10ng/ml, IFN-γ 50ng/ml, TNF-α 1ng/ml, CpG 100ng/ml, LPS 100ng/ml, Poly I:C 1ng/ml, 
3M001 3µM, 3M002 3µM). ChemR23 mRNA expression in macrophages stimulated for 24, 
48 and 72 hours with B. IL-4 and C. IL-13. All values were normalized for GAPDH and are 
presented relative to unstimulated macrophages (ctrl 24h). Bar indicates the means of 3 
independent experiments. D. ChemR23 protein expression on stimulated macrophages as 
measured by FACS. Values are presented relative to unstimulated macrophages. Bar indicates 
the means of 3 independent experiments. In black: 48 hours stimulation, dashed: 72 hours 
stimulation. E. Chemerin chemotaxis assay. Unstimulated, IL-4 and IL-13 stimulated 
macrophages were allowed to migrate toward 10nM chemerin. Bars show the mean migration 
index of 3 independent experiments. Migration of each set is shown relative to basal migration 
without the use of chemerin. *p<0.05, **p<0.01. 
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ChemR23 is transcribed from 3 transcription start sites, and is differentially spliced in human 
monocytes and macrophages 
We used the 5´ RACE to detect ChemR23 transcription start sites in human primary 
monocytes and macrophages. We identified 3 transcription starts in both monocytes and 
macrophages (Figure 2.3A and B). The first start site lies upstream of exon 1 in a region 
homologous to the promoter region and to the start site previously described in murine 
microglial cells [26]. The other two start sites are located in previously unreported genomic 
regions 12 950 and 21 370 base pairs (bp) downstream from P1, respectively.  
To analyze the functionality of the putative promoter regions upstream of the identified 
transcription starts, fragments of 500 bp and 1000 bp for each promoter were cloned upstream 
of the firefly luciferase gene, and the luciferase activity was measured in transfected THP1 
macrophages. The promoters upstream of exon 1 (P1) and 4 (P3) increased transcription of 
the reporter gene, while the promoter upstream of exon 3 (P2) showed only basal activity 
similar to the promoterless control vector, suggesting it may only be essential in other cell 
types (Figure 2.4A).  
In addition, the RACE experiment indicated that several ChemR23 mRNA isoforms are 
transcribed from promoter P1 located upstream of exon 1. To characterize these splice forms, 
we performed several RT-PCR reactions with primers specific for each exon. We identified 3 
splice variants in macrophages and 4 in monocytes for mRNAs starting with exon 1 
(transcribed from P1), and we confirmed the presence of ChemR23 mRNAs starting with 
exon 3 (transcribed from P2) and exon 4 (transcribed from P3) (Figure 2.3B) with no 
differential splicing. 
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Figure 2.3: ChemR23 transcription start sites and mRNA isoforms in monocytes and 
macrophages 
A. Nested RT-PCR products after RACE visualized on a 2% agarose gel. Race specific nested 
amplification using in combination with 5’RACE adapter nested inner primer the following 
gene specific primers: I. coding region specific reverse primer I., II. coding region specific 
reverse primer II, III. exon 5 specific reverse primer. B. Schematic of all differently spliced 
products identified by RACE and RT-PCR in monocytes and macrophages. Boxes represent 
exons and lines introns. The grey boxes represent the ChemR23 coding region. Numbers 
represent lengths of exons and introns in bp. ChemR23 gene is located on chromosome 12, 
contig 12q24.1. Intercontig position of transcription start sites: start site in exon 1: 108733094, 
start site in exon 2: 108720144, start site in exon 3: 108711724. 
In M1 macrophages, ChemR23 is preferentially transcribed from promoter P3  
To asses, which of the indentified promoters drives the increased transcription of ChemR23 in 
M1 macrophages, we quantified all mRNA variants transcribed from P1 and P3 in 
unpolarized, LPS and IFN-γ stimulated M1 macrophages. While the mRNA transcribed from 
P1 remained on the same level after IFN-γ and LPS stimulation, the mRNA transcribed from 
P3 increased 5 to 10 fold, respectively (Figure 2.4B). To locate the regulatory elements 
responsible for the transcriptional activation in the promoter region P3, we performed 
luciferase activity assays in THP1 macrophages transfected with a plasmid containing 1000pb 
of promoter P3 upstream of the luciferase gene. However, no increase in luciferase activity 
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was observed after stimulation of these macrophages with LPS or IFN-γ (data not shown). 
Congruent with the lack of induction of luciferase activity by LPS and IFN-γ, in silico 
analysis of the promoter P3 using the software MatInspector from Genomatix [27] did not 
predict any NF-κB, AP1, IRF-3 transcription factor binding sites, or IRF-1, IRF-9 and STAT-
1 binding sites necessary for TLR-4 [28] and IFN-γ signaling [29], respectively. 
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Figure 2.4: ChemR23 transcription from alternative promoters 
A. Luciferase activity measured in THP-1 macrophages transfected with the luciferase gene 
under the control of different ChemR23 promoter fragments. P1 - promoter upstream of 
exon 1, P2 - promoter upstream of exon 3, P3 - promoter upstream of exon 4. Bars represent 
the fold induction relative to the promoterless vector pGL4.18, which was used as a negative 
control (NC). All experiments were done 3 times in triplicate. Firefly luciferase activity was 
normalized by the Renilla luciferase activity. B. Absolute quantification of ChemR23 mRNA 
variants transcribed from P1 (black) and P3 (white). ChemR23 mRNA was quantified in 
unstimulated and IFN-γ and LPS stimulated primary human macrophages (24h). Values were 
normalized to GAPDH mRNA copy numbers. Bars indicate the mean of 3 independent 
experiments as fold induction of control. *p<0.05, **p<0.01. 
RvE1 signaling in M1 macrophages 
Our results show that resting and M1 macrophages express functional ChemR23 on their 
surface while M2 macrophages do not. We therefore surmised that the pro-resolving actions 
of RvE1 must be mediated through ChemR23 on resting or inflammatory macrophages. To 
investigate whether RvE1 causes a re-polarization of inflammatory M1 macrophages to an 
 38
M2 like phenotype, we sequentially stimulated primary human macrophages with LPS 
followed by either RvE1, IL-4 (control stimulus for M2 polarization), or medium without 
stimulus, and characterized the polarization phenotype of the macrophages. As expected, LPS 
stimulated M1 macrophages exhibited an increased transcription of IL-1β, TNFα and cell 
surface expression of CD80 [25,30]. Upon removal of the stimulus, IL-1β, TNFα and 
ChemR23 mRNA and CD80 protein levels returned to levels comparable to untreated 
macrophages. (Figure 2.5 and Figure 2.6A). Stimulation of these M1 macrophages with RvE1 
lead to a similar reversal of IL-1β, TNFα and ChemR23 transcription. In contrast, RvE1 
increased IL-10 transcription but not secretion, while RvE1 and IL-4 lead to a small but not 
significant increase in CD80 expression (Figure 2.6). In addition, only IL-4 increased CD206 
expression in M1 macrophages. These data indicate that RvE1 may have the potential to re-
polarize M1 macrophages toward an anti-inflammatory phenotype different from the M2 
polarization triggered by IL-4.  
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Figure 2.5: Quantification of cytokine and ChemR23 mRNA levels following re-
stimulation of LPS activated primary human M1 macrophages with RvE1 
A. TNFα . B. IL-1β. C. IL-10 D. ChemR23. Upper line – initial 3 day stimulation, bottom 
line – re-stimulation. Ctrl 0d – unstimulated macrophages day 0, med – medium with no 
stimulus. All values were normalized for GAPDH and are presented relative to unstimulated 
macrophages day 0. Bars indicate the mean of 3 independent experiments as fold induction 
of control. *p<0.05, **p<0.01. 
 
 
 39
 IL-10
0
500
1000
1500
Ctrl 0 med LPS LPS LPS LPS 
 -  -  - med IL-4 RvE1
CD 206
0
3000
6000
Ctrl 0 med LPS LPS LPS LPS 
 -  -  - med IL-4 RvE1
M
FI
CD 80
0
250
500
Ctrl 0 med LPS LPS LPS LPS 
 -  -  - med IL-4 RvE1
M
FI
**
A B
C
Fo
ld
in
du
ct
io
n
**
**
Figure 2.6: Cell surface expression of CD80 and CD206 and secretion of IL-10 
following re-stimulation of LPS activated primary human M1 macrophages with RvE1 
A. CD80 protein expression measured by FACS. B. CD 206 (mannose receptor) protein 
expression measured by FACS. C. IL-10 secretion measured by ELISA in supernatants of 
macrophages. Values are presented relative to unstimulated macrophages. 
Upper line – initial 3 day stimulation, bottom line – re-stimulation. Ctrl 0d – unstimulated 
macrophages day 0, med – medium with no stimulus. Bar indicates the means of 3 
independent experiments. *p<0.05, **p<0.01.  
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2.1.5 Discussion 
Classically activated M1 macrophages secreting high levels of inflammatory cytokines are 
implicated in the initiation of and in sustaining inflammation [31], while alternatively 
activated M2 macrophages have anti-inflammatory properties and are associated with wound 
healing and tissue repair [3]. As a receptor for the chemoattractant chemerin and the lipid 
mediator RvE1, ChemR23 plays a role in immigration of macrophages to the inflamed area 
[12] as well as in the resolution of inflammation [13,23]. However, little is known about its 
regulation during different stages of inflammation or in different activation states of 
macrophages. Here we show that ChemR23 transcription and protein expression increase 
during differentiation of monocytes to macrophages and are further amplified in classically 
activated M1 macrophages in vitro. M1 macrophages migrate towards the ChemR23 ligand 
chemerin and increase IL-10 transcription in response to RvE1 stimulation, suggesting that 
RvE1 may re-polarize human M1 macrophages to an intermediate resolution phase 
phenotype. In contrast, ChemR23 expression is not detectable in alternatively activated M2 
macrophages, which are also not responsive to ChemR23 signaling.  
The regulation of ChemR23 expression was previously studied in mouse macrophages, where 
ChemR23 was down-regulated by inflammatory stimuli such as TLR ligands (LPS, CpG) and 
inflammatory cytokines, and upregulated by TGFβ [32,33]. The authors of these studies 
concluded that ChemR23 has a role in naive and anti-inflammatory macrophages only. In 
contrast, we and others [13] show that ChemR23 mRNA levels increase in human monocytes 
and macrophages after stimulation with LPS or the inflammatory cytokines TNF-α and IFN-γ, 
suggesting that there are differences between mice and men in the regulation and eventually 
function of ChemR23. This notion would be supported by the fact that chemerin has 
ChemR23 dependent anti-inflammatory and protective effects in some mouse models of 
inflammation [34,35], while in humans increased chemerin concentrations are associated with 
pathologies connected with chronic and systemic inflammation [36,37,38,39] and chemerin 
was shown to induce inflammatory signaling in chondrocytes [40]. The differential expression 
pattern of ChemR23 on stimulated macrophages and the possible opposite effect of chemerin 
on inflammation between mice and men may indicate that the role of ChemR23 signaling 
differs between the two species.  
We report the identification of 3 ChemR23 transcription start sites in human primary 
monocytes and macrophages and show that ChemR23 is differentially spliced. Basal 
transcription in human monocytes and naive macrophages is driven equally from promoters 
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P1 and P3 and transcripts from promoter P1 are differentially spliced leading to 4 splicing 
variants in monocytes and 3 in macrophages. All differentially spliced exons are non-coding 
and have no effect on the final size and sequence of the protein. However, such differential 
splicing and the presence of various mRNA isoforms may represent an additional way of 
ChemR23 regulation, as sequence characteristics within the 5’ UTR play an important role in 
the differential regulation of translation efficiency and mRNA stability [41].  
From the three identified promoters only P1 and P3 are used in monocytes and macrophages, 
while transcription from promoter P2 is basically absent. Similarly, two distinct start sites and 
several differentially spliced isoforms were reported for the mouse homologue of ChemR23 
(DEZ) in mouse neuroblastoma and microglia cells [26,42]. Such usage of alternative 
promoters has been previously described to enable differential transcriptional regulation in 
different cell types or developmental stages, or upon stimulation [43]. Recent evidence 
suggests that more than 50% of human protein coding genes have multiple alternative 
promoters [44]. Promoter P2 is therefore likely to be used in other cells types than monocytes 
and macrophages.  
Stimulation of primary human macrophages with LPS or IFNy increased transcription 
downstream of promoter P3, indicating a preferential use of this promoter in M1 
macrophages. However, we did not detect transcription factor binding sites necessary for 
TLR-4 [28] or IFN-γ signaling [29] within 1000 bp upstream of the transcriptional start site, 
neither by transcriptional activity experiments using the reporter constructs nor by in silico 
analysis. These results indicate that the regulatory elements necessary for TLR-4 and IFN-γ 
signaling are located either further upstream or downstream of the transcription start site. This 
would be in agreement with the findings that transcriptional enhancer elements can be located 
in the first intron [45,46] or even several kb from the transcription start site [47].  
Our results show that only naive and inflammatory M1 macrophages can be responsive to 
ChemR23 mediated triggering, which implicates that RvE1 exerts its pro-resolving actions 
only on these macrophage phenotypes. In an effort to assess whether RvE1 initiates re-
polarization of M1 macrophages, we measured the expression of cytokines and surface 
markers characteristic for M1 or M2 macrophages after re-stimulation of M1 macrophages 
with RvE1. Re-stimulation resulted in a mild but not significant increase in CD80 expression, 
similar to the typical M2 stimulus IL-4, while in contrast to IL-4, RvE1 did not induce 
mannose receptor expression but increased IL-10 transcription without increasing translation. 
Hence, re-stimulation of M1 macrophages with RvE1 may lead to sustained CD80 expression 
and to increased IL-10 expression, suggesting an anti-inflammatory and eventually pro-
 43
resolving effect of RvE1 on M1 macrophages. However, this pro-resolving effect does not 
result in an IL-4 mediated M2 polarizing effect but rather leads to an intermediate 
macrophage phenotype.  
Intermediate macrophage phenotypes have recently been indentified during the resolution 
phase of inflammation in vivo. Bystrom et. al. isolated resolution phase macrophages which 
secreted high levels of anti-inflammatory IL-10 but little inflammatory cytokines and which 
expressed the mannose receptor (properties of M2 macrophages) as well as high levels of 
COX-2 (a property of M1) [7]. A transcriptomic analysis showed that resolution phase 
macrophages transcribe high levels of IL-10, COX-2 and of the mannose receptor, and despite 
the low secretion, also high levels of inflammatory cytokines [48]. In the same mouse model, 
peritoneal injection of RvE1 induced the formation of CD11blow macrophages with high 
phagocytic capacity, reduced TNFα and increased IL-10 secretion supporting the pro-
resolution effect of RvE1 in mouse macrophages [49]. Although the characteristics of the 
resolution phase mouse macrophages described in the above mentioned studies differ from the 
characteristics of the RvE1 re-stimulated M1 human macrophages in our experiments, 
increased IL-10 expression seems to be a common denominator of such intermediate pro-
resolving macrophages. In agreement with these data, we show that RvE1 induced IL-10 
transcription in primary human M1 macrophages suggesting that RvE1 may re-polarize 
human primary M1 macrophages towards a resolution phase macrophage. 
Unexpectedly, we observed no increase of IL-10 secretion upon re-stimulation of M1 
macrophages with RvE1, arguing for post-transcriptional regulation of IL-10 secretion. 
Indeed, IL-10 secretion was shown to be regulated by microRNAs [50] and AU-rich elements 
present in the 3′-UTR of the IL-10 mRNA [51], which may explain the low IL-10 secretion 
observed in RvE1 re-stimulated M1 macrophages despite increased transcription rates. 
Alternatively, differences in the experimental set-up may lead to the not congruent results 
between the in vivo mouse studies and our in vitro human studies. Following systemic 
application of RvE1 in mice multiple cell types are affected such as endothelial cells through 
ChemR23 [11,13] and neutrophils through the BLT1 receptor [52], which in turn may 
stimulate macrophages. In contrast, these additional stimuli lack in our in vitro study on 
primary human macrophages.  
In summary, we show that ChemR23 is tightly regulated in response to inflammatory and 
anti-inflammatory stimuli. The high expression of ChemR23 in naive and M1 macrophages 
supports the role of ChemR23 in the attraction of macrophages to inflamed tissue by chemerin 
and in the initiation of resolution of inflammation through RvE1 signaling in human 
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macrophages. In contrast, the role of ChemR23 mediated signaling is limited in M2 
macrophages. 
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2.1.7 Supplementary data 
Supplementary table 2.1: Primers for quantitative PCR, 5´- 3´ 
Gene Forward Reverse 
ChemR23 
all RNA variants TTGGCTGAGGACTCACATTG CTGATCTTGCACATGGCTGT 
ChemR23 variants 
transcribed from P1 TCAGAGGGGGATCTTGAATG GGGGATAAGTCCTCCAAAACCA 
ChemR23 variants 
transcribed from P3 AAACTCTGGAAGGAGACATGAGGAACT GGGGATAAGTCCTCCAAAACCA 
GAPDH CCCATGTTCGTCATGGGTGT TGGTCATGAGTCCTTCCACGATA 
Human IL-1β TACCTGTCCTGCGTGTTGAA TCTTTGGGTAATTTTTGGGATCT 
Human TNFα GAGTGACAAGCCTGTAGCCCATGTT GTAGCA 
GGCAATGATGATCCCAAAGTAGAC
CTGCCCAGACT 
Human IL-10 GATCCAGTTTTACCTGGAGGAG CCTGAGGGTCTTCAGGTTCTC 
 
Supplementary table 2.2: Primers for RACE, 5´- 3´ 
 Forward Reverse 
ChemR23 
inner primers GCTGATGGCGATGAATGAACACTG 
I. GGGGATAAGTCCTCCAAAACCA 
II. TCCTGGTCACCCTGGCTTCC 
III. AGTCCTCAGCCAATCAGTCCCTGT 
ChemR23 
outer primers GAACACTGCGTTTGCTGGCTTTGATG AATCCCGAGGAAGCAGACGAT 
 
Supplementary table 2.3: Primers for differential splicing, 5´- 3´ 
Exon Forward Reverse 
Exon 1 TCAGAGGGGGATCTTGAATG - 
Exon 2 TGGTCACAGCAACTCACCAT AGATGCCATCAGCTTCTGCT 
Exon 3 AGTGCTCAGGGTGGGGGACA - 
Exon 4 AAACTCTGGAAGGAGACATGA - 
Exon 5 - AGTCCTCAGCCAATCAGTCCCTGT 
Coding exon - I. GGGGATAAGTCCTCCAAAACCA II. TCCTGGTCACCCTGGCTTCC 
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Supplementary table 2.4: Primers for promoter subcloning, 5´- 3´ 
Promoter Forward 1000 bp Forward 500 bp Reverse 
P1 
TACGCTCGAGTGGTGGTTCA
CACGGCTTAC 
GAGACTCGAGTGATGGGGTG
ACCCTGAG 
GAAGAAGCTTCATTCAAGA
TCCCCCTCTG 
P2 
CTGGCTCGAGTCTCAAACTC
CTGGCTTCAAG 
GAGTCTCGAGTGCTTTCTGA
AATGCGATTG 
GAGTAAGCTTGTCCACAGC
ACCTGAATGT 
P3 
TAGACTCGAGTTGGGGCCAC
CAAAGGCACC 
CAGACTCGAGAACAGCCAG
TACAGCTAGAAT 
TGTAAAGCTTCCACCTCCCT
ATGTTAGTTC 
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2.2.1 Abstract  
Chemerin is a peptide chemoattractant for macrophages and an adipokine regulating 
adipocyte differentiation and metabolism. Plasma chemerin is increased in chronic 
inflammatory diseases and in obesity. As inflammation and obesity are risk factors for 
coronary artery disease (CAD), we investigated possible associations of plasma chemerin 
with inflammatory markers and atherosclerosis in a CAD case-control study (n=470). 
Chemerin levels were associated with C-reactive protein, BMI and LDL levels, and 
negatively associated with HDL levels. Mean plasma chemerin levels were similar in controls 
and CAD patients but significantly higher in CAD patients not taking low dose aspirin. To 
investigate the mechanism of chemerin reduction by aspirin, we analyzed chemerin 
expression in hepatocytes and adipocytes treated with aspirin in the presence and absence of 
inflammatory cytokines. Chemerin expression was upregulated by pro-inflammatory stimuli 
in adipocytes but not in hepatocytes. Treatment of stimulated hepatocytes and adipocytes with 
aspirin did not affect chemerin expression. However, treatment of inflammatory M1 
macrophages with aspirin reduced secretion of the pro-inflammatory cytokines IL-1β and IL-
6, and increased secretion of the anti-inflammatory IL-10. In summary, we show that plasma 
chemerin levels are associated with markers of inflammation and that they are significantly 
higher in CAD patients not treated with low dose aspirin. In addition, we show that low dose 
aspirin treatment reduces pro-inflammatory cytokine secretion by macrophages, which may 
lead to reduced chemerin secretion by adipocytes and may be a reason for the lower chemerin 
levels in the circulation of CAD patients on low dose aspirin.  
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2.2.2 Introduction 
Cardiovascular disease is the leading cause of morbidity and mortality in developed countries 
and an emerging health problem worldwide. Coronary artery disease (CAD) is one of the 
most common forms of cardiovascular disease caused by progressive atherosclerotic lesion 
formation leading to narrowing of the arterial lumen [1]. 
The major independent risk factors for CAD are high blood pressure, elevated serum total and 
low-density lipoprotein cholesterol (LDL), low serum high-density lipoprotein cholesterol 
(HDL), diabetes mellitus, advanced age, and smoking [2]. Recently, central obesity and the 
metabolic syndrome associated with obesity have been identified as additional risk factors. 
The adipose tissue is today recognized as an important player in obesity-mediated 
cardiovascular disease [3] not only through its role in energy storage but also due to its role as 
an active endocrine organ [4]. Disrupted lipid and glucose metabolism in obese adipose tissue 
and low systemic inflammation accompanying obesity accelerate the development of 
cardiovascular disease [5].  
Chemerin is an adipokine and a chemokine with a role in inflammation. It is secreted as a 
non-active precursor protein, which can be activated through cleavage of its C-terminus by 
proteases of the coagulation and fibrinolytic cascades, and proteases released from activated 
neutrophils or mature adipocytes [6,7]. Chemerin is highly expressed by adipocytes and after 
activation triggers the maturation of preadipocytes into adipocytes [8,9]. This role in 
adipocyte maturation is reflected by the positive correlation of chemerin plasma levels with 
the waist hip ratio and BMI [10,11,12], and by the decrease of plasma chemerin levels after 
bariatric surgery [13] in parallel to the decrease of body fat mass. In addition, chemerin has 
been detected in high amounts in inflammatory fluids [14,15,16] and in atherosclerotic lesions 
[17]. Chemerin is a chemoattractant for leukocytes and is thought to recruit macrophages to 
the site of inflammation [18].  
Given chemerin´s role in inflammation as a leukocyte chemoattractant and its function in 
adipogenesis, we hypothesized that plasma chemerin could be associated with human 
atherosclerosis. We therefore investigated the association of chemerin plasma levels with 
markers of atherosclerosis and with CAD in a human case-control study.  
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2.2.3 Material and Methods 
Case-control study 
A total of 323 men and 147 women from Zurich volunteered to participate in the study [19]. 
They all signed an informed consent form. The study was approved by the local Ethics 
Committee  and complies with the Declaration of Helsinki. The case group consisted of 249 
consecutive Caucasian patients with angiographically documented CAD with more than 50% 
stenosis in at least 1 coronary artery. The control group consisted of 221 Caucasians with 
angiographically negative results and individuals with no history of CAD, stroke, or 
peripheral vascular disease recruited from the general population. Risk factors and the use of 
medication were assessed by a questionnaire. The clinical chemistry analyses were carried out 
on a Roche-Hitachi Modular Clinical Chemistry analyzer using commercial tests from Roche 
Diagnostics (Rotkreuz, Switzerland).  
Power calculation 
The study has a power of 80% to detect a mean difference in chemerin plasma levels of ± 1.18 
ng/ml between cases and controls. 
Sample preparation and ELISA 
Plasma samples were collected consecutively and stored at – 20°C before analysis. Plasma 
was diluted 200x and total chemerin concentration was assessed with a commercially 
available human chemerin ELISA (R&D Systems) according to the manufacturer’s 
instructions. The antibodies used for the ELISA are raised against AAs 21 to 157 of human 
chemerin. Prochemerin as well as active forms of chemerin are therefore detected by the 
assay.  
Chemerin concentrations in 3T3-L1mouse adipocyte and Hep3B hepatocyte supernatants 
were measured using commercially available mouse and human chemerin ELISAs (R&D 
Systems) according to the manufacturer’s instructions. 
Cytokine concentrations in macrophage supernatants were measured with the Bio-Plex Pro 
multiplex ELISA assay (Bio-Rad, Cressier, Switzerland). Fluorescence signals were detected 
using the Luminex® 200TM System (Bio-Rad, Cressier, Switzerland). Median Fluorescence 
Intensity (MFI) as well as the concentration (pg/ml) was calculated by using the Bio-
PlexManagerTMsoftware provided by the manufacturer. 
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Cell culture experiments with cell lines 
Human Hep3B hepatocytes were grown in RPMI-1640 (Sigma-Aldrich) medium 
supplemented with 10% FBS (Sigma Aldrich), 2% L-glutamine (Invitrogen) and 1% 
Penicillin/Streptomycin (Sigma Aldrich) at 37°C and 5% CO2.  
Mouse 3T3-L1 preadipocytes were cultured in DMEM (Sigma Aldrich) supplemented with 
10% FBS and 1% Penicillin/Streptomycin. 2d after confluence, differentiation was initiated 
by addition of 1 μg/ml insulin (Sigma Aldrich), 115 μg/ml 1-methyl-3-isobutylxanthine 
(IBMX; Sigma Aldrich) and 1 μM dexamethasone (Sigma Aldrich) for 2 days. Then the 
medium was changed to DMEM, 10% FBS, 1% Penicillin/Streptomycin and 1 μg/ml insulin 
for 2 days. Thereafter, the cells were maintained in the preadipocyte medium.  
Cell culture experiments with primary human macrophages 
Human leukocytes were isolated from buffy coat (Blutspendezentrum Zurich, Switzerland) 
with Histopaque-1077 gradient (Sigma Aldrich). Peripheral blood monocytes were purified by 
capturing with anti-CD14 antibodies coupled to MACS Micro beads (Miltenyi Biotec, 
Bergisch Glad, Switzerland) according to the manufacturer’s instructions. Monocytes were 
allowed to differentiate into macrophages for 7 days at 37°C in RPMI-1640 supplemented 
with 5% FBS, 5% human AB serum (Sigma Aldrich), 1% Penicillin/Streptomycin and 5% 
CO2.  
Relative quantification of gene expression 
RNA was isolated using the RNeasy mini kit (Qiagen, Canada). cDNA was prepared by 
reverse transcription from 1μg total RNA using the Superscript III reverse transcriptase 
(Invitrogen). Chemerin and cytokine mRNA levels were quantified by real-time PCR using 
the SYBR Green master mix kit (Roche Diagnostics, Rotkreuz, Switzerland) on the Light 
Cycler 480 (Roche Diagnostics). The reactions were performed under the following 
conditions: preheating 10min 95°C followed by 45 cycles of denaturation 5sec 95°C, 
annealing 10sec, 60°C and extension 6sec 72°C. Relative gene expression was normalized to 
GAPDH in human Hep3B hepatocytes and macrophages, and cyclophilin A in mouse 3T3-
L1adipocytes. The primers are listed in the Supplementary table 2.7. 
Statistical analysis 
The statistical analysis was performed using the R software 2.12.0. Two sided t-tests were 
applied to investigate the association of chemerin levels with binomial variables. Uni-variate 
analyses of the association of chemerin with other continuous variables were carried out using 
 56
the Spearman correlation. Linear regression model was used for the multi-variate analysis of 
the association of chemerin with CAD risk factors. Two sided t-test and factorial ANOVA 
were used for the comparison of chemerin concentrations between controls and cases, and 
between controls and patients with and without aspirin therapy, respectively. The equality of 
variances of the patient and control samples, and of patients taking and not taking aspirin 
were tested using the F-test. Logistic regression was used to assess whether plasma chemerin 
levels are predictive of CAD. P-values lower than 0.05 were considered statistically 
significant. 
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2.2.4 Results 
Plasma chemerin levels correlate with risk factors for CAD in healthy volunteers 
The characteristics of the case-control sample are shown in Table 2.1. To determine whether 
chemerin levels are associated with risk factors for CAD in the general population, we 
investigated the association of plasma chemerin levels with these risk factors in controls only. 
Chemerin was positively associated with BMI (r = 0.23, p < 0.0001), cholesterol (r = 0.24, 
p < 0.0001), LDL (r = 0.16, p = 0.017), hypertension (t = 2.53, p = 0.050), hsCRP (r = 0.25, 
p < 0.0001) and negatively associated with HDL levels (r = -0.21, p = 0.002) in healthy 
volunteers. These associations remained significant when analyzed in cases and when 
analyzed in the entire case-control study. In cases not taking aspirin, the associations with 
LDL and hypertention were no longer significant but chemerin levels remained associated 
with BMI, cholesterol, high sensitivity CRP (hsCRP) and HDL (Supplementary table 2.5). No 
difference in plasma chemerin levels was found between sexes and there was no association 
of plasma chemerin levels with smoking, age or diabetes. 
 
Table 2.1: Characteristics of controls and cases 
 Controls (n=221) Cases (n=249) P value 
Age (years) 59 (53; 66)* 63 (57; 71) 0.0001 
Males (%) 57 79 <0.0001 
Body-mass index (BMI) 25.8 (23.0;28.0) 26.6 (24.4;29.7) 0.0001 
Obesity (BMI ≥ 30) (%) 12 18 0.0101 
Hypertension (%) 28 45 0.0002 
Diabetes (%) 3 20 <0.0001 
Current Smokers (%) 13 16 0.0002 
Ever Smoked (%) 31 58 <0.0001 
Aspirin treatment (%) NA 88  
Statin treatment (%) NA 80  
Creatinine (μmol/l)  90.0 (82.5;98.5) 89.0 (80.0;99.0) 0.38 
hsCRP (mg/l)  2.4 (0.6;2.7) 1.8 (0.9;3.8) 0.0015 
Cholesterol (mmol/l) 5.9 (5.2;6.4) 5.1 (4.3;5.9) <0.0001 
HDL (mmol/l) 1.6 (1.3;1.9) 1.2 (1.1; 1.4) <0.0001 
LDL (mmol/l)  3.5 (2.8; 4.0) 3.2 (2.4; 3.8) 0.006 
Chemerin (ng/ml) 164.0 (146.7;189.4) 169.6 (143.6-201.1) 0.41 
*median and interquartile ranges are shown. 
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Plasma chemerin levels are independently associated with hsCRP, cholesterol and HDL 
To investigate whether the observed associations of plasma chemerin levels with CAD risk 
factors are independent of each other, we used a step-wise linear regression analysis initially 
including all associated variables (Table 2.2). In the step-wise multiple linear regression 
analysis, hsCRP and cholesterol were positively associated with plasma chemerin levels while 
HDL levels were negatively associated with plasma chemerin levels in controls. The same 
parameters also remained significantly associated in a multivariate analysis across the entire 
case-control study after adjusting for case status and medication. 
Table 2.2: Multivariate regression model to predict chemerin levels in controls 
 Estimate total P value 
hsCRP 1.954 0.0041 
Cholesterol 7.579 0.0012 
HDL -19.295 0.00023 
 
Plasma chemerin levels are increased in CAD patients not taking aspirin 
Although plasma chemerin levels were associated with several risk factors, there was no 
significant difference of the mean chemerin levels between CAD cases and controls 
(p = 0.41). However, the range of measured chemerin differed significantly between the two 
groups (p= 0.0038), with a larger range seen in the case group. We searched for an 
explanation for this broad range in chemerin plasma concentrations in cases by stratification 
of the cases according to drug treatment. A post-hoc analysis revealed no difference in 
chemerin plasma levels in CAD patients not taking statins and those on statin treatment. 
However, chemerin levels were significantly higher in plasma of CAD patients not 
undergoing aspirin treatment than in patients on aspirin treatment or in controls (cases treated 
vs. not treated, p = 0.009; controls vs. not treated cases, p = 0.007; ANOVA p = 0.005) 
(Figure 2.7). The difference in chemerin levels remained significant after adjusting for BMI. 
Characteristics of the two CAD patient groups are shown in Supplementary table 2.6. 
 
 Figure 2.7: Plasma chemerin levels are higher in CAD patients not taking aspirin.  
Box plot diagram of plasma chemerin levels in healthy controls (Controls),  
CAD patients on low dose aspirin medication (Aspirin) and CAD patients not taking 
aspirin (No aspirin); * p < 0.05 
IL-1β reduces chemerin expression in hepatocytes; aspirin has no effect  
Next, we sought the origin of elevated chemerin and investigated the mechanism by which 
aspirin reduces chemerin secretion into plasma. Chemerin is mainly expressed by the 
hepatocytes in the liver, and adpocytes in white adipose tissue [9,10], and chemerin 
expression and secretion were shown to be directly upregulated by TNFα [20,21] and IL-1β 
[22] in adipocytes. Liver and adipose tissue are currently believed to be the main source of 
plasma chemerin [23]. Therefore we postulated that these tissues are be responsible for its 
increase in plasma during systemic inflammation seen in obesity and CAD. 
We analyzed the expression of chemerin and its regulation by inflammatory cytokines in the 
presence and absence of aspirin in hepatocytes using concentrations of aspirin expected in 
human plasma after a low dose of (100 mg/day, 2 mg/l) and high dose (400 mg/day, 20 mg/l) 
aspirin treatment (Produktmonographie Aspirin Cardio, Bayer AG; Arzneimittelkompedium 
der Schweiz). Non-stimulated hepatocytes expressed and secreted chemerin. Stimulation with 
IL-1β and TNFα reduced chemerin transcription, and stimulation with IL-1β also protein 
secretion (Figure 2.8 A and B). IL- 6 stimulation had no effect on chemerin mRNA 
expression and protein secretion in hepatocytes (data not shown). In addition, simultaneous 
treatment of hepatocytes with aspirin did not significantly change chemerin expression or 
secretion in control or cytokine stimulated hepatocytes (Figure 2.8 A and B). Taken together 
these data indicate that inflammation moderately decreases hepatocyte chemerin secretion and 
that aspirin treatment does not influence hepatocyte chemerin secretion.  
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Figure 2.8: Chemerin expression and secretion in hepatocytes and adipocytes is not 
altered by aspirin. 
Chemerin mRNA levels and secreted chemerin from Hep3B hepatocytes and 3T3-L1 
adipocytes stimulated for 48 hours with 10 ng/ml IL-1β, 10 ng/ml IL-6 and 25 ng/ml 
TNFα in the absence and presence of aspirin. A) Chemerin mRNA in Hep3B 
hepatocytes. B) Chemerin protein secreted by Hep3B hepatocytes. C) Chemerin mRNA 
in 3T3-L1 adipocytes. D) Chemerin protein secreted by 3T3-L1 adipocytes. Indicated 
stimulation of the cells (white), co-stimulation of the indicated stimulation with 2 mg/l 
aspirin (hatched) and with 20 mg/l aspirin (black). mRNA levels were normalized to 
GAPDH levels and the protein levels were normalized to the control value. The chemerin 
concentration in the supernatant of hepatocytes and adipocytes was in the range of ng/ml. 
Bars represent the mean +/- standard deviation of 3 independent experiments performed 
in triplicates. * p < 0.05, ** p < 0.01.  
Cytokines but not aspirin regulate chemerin expression in adipocytes 
In adipocytes (Figure 2.8 C and D), we could confirm the previously published stimulatory 
effect of TNFα and IL-1β on chemerin production [20,21] [22], while no effect was observed 
with IL-6. However, similar to the findings in hepatocytes, aspirin co-treatment of both 
control and cytokine-stimulated cells did not significantly change chemerin mRNA or 
secreted protein levels (Figure 2.8 C and D), suggesting that aspirin does not directly regulate 
chemerin expression in adipocytes.  
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Aspirin reduces IL-1β and IL-6 expression and increases IL-10 expression in pro-
inflammatory M1 macrophages 
Obesity is associated with low level inflammation and with increased accumulation of 
mononuclear immune cells within the adipose tissue [24]. Macrophages in obese adipose 
tissue have in the majority the M1 phenotype and were shown to secrete increased levels of 
inflammatory cytokines including IL-1β and TNFα [25]. We hypothesized that aspirin would 
reduce the pro-inflammatory status of M1 macrophages and in turn lead to reduced chemerin 
secretion by adipocytes. To test this, we induced the M1 phenotype in macrophages by LPS 
stimulation in the absence and presence of aspirin. LPS stimulated macrophages secreted high 
levels of the inflammatory cytokines TNFα, IL-1β and IL-6. Aspirin co-treatment reduced IL-
1β transcription, and IL-1β and IL-6 secretion from macrophages in a dose dependent manner 
but had no impact on TNFα expression. The higher dose of aspirin (20 mg/l) also significantly 
increased IL-10 secretion (Figure 2.9). These data show that even low dose aspirin reduces 
the inflammatory state of macrophages altering the secretion of pro- and anti-inflammatory 
cytokines. This as a consequence could lead to reduced stimulation of chemerin expression in 
adipocytes of inflamed adipose tissue. 
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Figure 2.9: Aspirin reduces cytokine expression and secretion of inflammatory M1 
macrophages 
Human primary macrophages were stimulated for 48 hours with 100 ng/ml LPS for 
polarization into M1 macrophages in the presence and absence of aspirin. A) IL-1β 
mRNA in M1 macrophages. B) TNFα mRNA in M1 macrophages. C) Cytokines secreted 
by M1 macrophages. Macrophages stimulated with LPS alone (white), co-stimulation of 
LPS with 2 mg/l aspirin (hatched) and with 20 mg/l aspirin (black). mRNA levels were 
normalized to GAPDH levels and the protein levels were normalized to the control value. 
The concentration of the secreted cytokines in the supernatant was in the range of pg/ml. 
Bars represent the mean +/- standard deviation of 3 independent experiments performed 
in triplicates. * p < 0.05, ** p < 0.01 
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2.2.5 Discussion 
We show that plasma chemerin levels correlate with multiple risk factors for the metabolic 
syndrome and CAD. In conformity with previous smaller studies, chemerin levels are 
positively associated with BMI, total cholesterol, LDL, hsCRP, hypertension, and negatively 
associated with HDL levels. Despite the association with multiple risk factors for CAD, there 
is no direct association of chemerin plasma levels with CAD. However, we observed 
increased plasma chemerin levels in CAD patients not undergoing aspirin treatment, 
indicating that low dose aspirin reduces chemerin secretion. In scrutinizing the possible 
mechanism leading to the reduced chemerin secretion, we show that aspirin treatment 
diminishes the secretion of pro-inflammatory cytokines by M1 activated human primary 
macrophages possibly leading to reduced stimulation of chemerin transcription and secretion 
in adipocytes. In this manner, our data generate the hypothesis that low dose aspirin can 
reduce adipose tissue inflammation by lessening the inflammatory response of macrophages. 
Obesity is associated with increased infiltration of macrophages into the adipose tissue [24]. 
These macrophages have the pro-inflammatory M1 phenotype, while in lean adipose tissue 
mostly non-phlogistic M2 macrophages are observed [26]. M1 macrophages are a prominent 
source of inflammatory cytokines, which signal in a parakrine manner to the surrounding 
cells, and which are also released to the circulation [27]. Consequently, they contribute to the 
local and to the systemic low-grade inflammation. Our data show that inflammatory cytokines 
reduce chemerin secretion in hepatocytes and increase chemerin secretion in adipocytes, 
indicating that inflammation would augment chemerin secretion in the adipose tissue. 
Considering that hepatocytes in the liver and adipocytes in white adipose tissue are believed 
to be the major sources of plasma chemerin [23], our findings generate the hypothesis that 
increased plasma chemerin reflects adipose tissue inflammation. A role for plasma chemerin 
as a marker for adipose tissue inflammation is supported by the positive correlation of plasma 
chemerin with the inflammatory cytokines TNFα and IL-6 [28], the negative correlation with 
adiponectin and HDL [13,29], and the association with various markers of the metabolic 
syndrome in our and other studies [10,11,12,28]. However, we have to emphasize that the 
source of chemerin in human plasma has not been fully established and further research is 
necessary before chemerin can be proposed as a marker for adipose inflammation.  
In addition, we show evidence that even low dose aspirin can reduce inflammation and that 
low dose aspirin treatment is associated with lower plasma chemerin levels in CAD patients. 
Low dose aspirin is indicated for cardiovascular prophylaxis based on clinical trials showing 
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that aspirin in all doses reduced the risk of myocardial infarction, ischemic stroke, and 
vascular death [30]. Aspirin takes effect primarily by inhibiting the thromboxane A2 (TXA2) 
and prostaglandin biosynthesis by cyclooxygenases (COX). Low dose aspirin efficiently 
inhibits TXA2 production in platelets, which is necessary for its cardioprotective effects, while 
higher doses are necessary for the blocking of prostaglandin synthesis - the known anti-
inflammatory effect of aspirin [31]. In this context it is noteworthy that platelets store 
chemerin and release chemerin upon activation by thrombin [32], opening a second pathway 
for aspirin to reduce plasma chemerin levels through inhibition of platelet activation. 
However, whether this locally and intermittently released chemerin would substantially 
contribute to human plasma chemerin levels is questionable and will have to be shown in the 
future.  
Our findings show for the first time that even low dose aspirin has anti-inflammatory effects 
on primary human macrophages, which may contribute to the clinical benefits of aspirin in the 
treatment of cardiovascular disease. This is in agreement with the findings of the Physicians 
Health Study, which showed that low dose aspirin was especially beneficial for the prevention 
of myocardial infarction in participants with elevated CRP [33]. On the molecular level, there 
is an indication that that aspirin redirects the COX-2 enzyme from the production of the pro-
inflammatory prostaglandins to the production of the pro-resolving aspirin-triggered lipid 
mediators [34]. These aspirin-triggered lipid mediators induce the resolution of inflammation 
[35] and are produced especially under low dose aspirin regimens [36]. Intriguingly, aspirin-
triggered lipid mediators were also reported to improve the inflammatory status of obese 
adipose tissue [37,38].  
Although plasma chemerin levels were associated with markers of inflammation, and the 
metabolic syndrome in human studies, it is currently not clear whether increased chemerin 
levels influence atherosclerosis in humans. Several small case-control studies have been 
carried out showing contentious results for the association of chemerin plasma levels with 
CAD. While two small studies in Asians showed an association of plasma chemerin levels 
with atherosclerotic diseases [39,40], a third study in Caucasians could not corroborate these 
findings [28]. Our study indicates that we will have to correct for confounding factors such as 
aspirin treatment to dissect the role of chemerin in human atherosclerosis. In addition, it might 
be local rather than systemic levels of chemerin that influence atherosclerosis. Systemic 
overexpression of human chemerin in mice lacking the LDL-receptor did not affect 
atherogenesis [41]. In contrast, chemerin levels in the epicardial adipose tissue were 
associated with CAD in Han Chinese [42] and chemerin expression in the periaortic adipose 
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tissue was shown to correlate with aortic atherosclerosis [17]. These results indicate that 
locally activated chemerin may influence the local inflammatory state and contribute to 
atherogenesis, probably through chemoattraction of macrophages [18] and activation of cell 
adhesion allowing immigration of macrophages into the arterial wall [43].  
In conclusion we show that plasma chemerin is associated with systemic markers of 
inflammation and components of the metabolic syndrome. In addition we show that low dose 
aspirin treatment reduces pro-inflammatory cytokine secretion by macrophages, which may 
lead to reduced chemerin secretion by adipocytes and may be a reason for the lower chemerin 
levels in the circulation of CAD patients on low dose aspirin.  
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2.2.7 Supplementary data 
Supplementary table 2.5: Correlations with CAD risk factors in cases not taking aspirin 
 Spearman coef. P-value 
BMI 0.24 0.0002 
Cholesterol 0.14 0.0224 
LDL 0.1 0.1358 
hsCRP 0.23 0.0002 
HDL -0.27 0.0000 
 T-value P-value 
Hypertension 0.24 0.8103 
 
Uni-variate analyses of the association of chemerin with continuous variables were 
carried out using the Spearman correlation.Two sided t-test was applied to investigate the 
association of chemerin levels with hypertension.  
 
Supplementary table 2.6: Characteristics of cases with and without aspirin treatment 
 Aspirin (n=218) No aspirin (n=29) P value 
Age (years) 63 (57;71)* 66 (60; 73) 0.34 
Males (%) 78 83 0.77 
Body-mass index (BMI) 26.4 (24.4;29.7) 27.9 (25.3;30.3) 0.94 
Obesity (BMI ≥ 30, %) 19 28 0.50 
Hypertension (%) 47 31 0.15 
Diabetes (%) 21 20 1 
Current Smokers (%) 17 14 0.92 
Ever Smoked (%) 56 76 0.066 
Statin treatment (%) 80 83 0.95 
Creatinine (μmol/l) 88.0 (79.3;97.0) 91.0 (82.0;108.0) 0.25 
hsCRP (mg/l) 1.8 (0.9;3.6) 3.2 (1.8;6.2) 0.15 
Cholesterol (mmol/l) 5.2 (4.4-5.9) 4.5 (4.0;6.0) 0.79 
HDL (mmol/l) 1.3 (1.1;1.4) 1.1 (1.0; 1.4) 0.029 
LDL (mmol/l) 3.3 (2.5-3.9) 2.7 (2.3-3.5) 0.94 
Chemerin (μg/l) 168.6 (140.6;195.1) 182.5 (167.3;214.7) 0.009 
 
*median and interquartile ranges are shown. For 2 CAD patients no information about 
aspirin treatment was available. F-test for the equality of the variances of chemerin levels 
in the two groups:  
F = 1.0407, p-value = 0.8305 
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Supplementary table 2.7: Primers for quantitative PCR, 5´- 3´ 
Gene Forward Reverse 
Human 
chemerin TGGAAGAAACCCGAGTGCAAA CCCCATAGAGACCCAAGTTCT 
Human 
GAPDH CCCATGTTCGTCATGGGTGT TGGTCATGAGTCCTTCCACGATA 
Mouse 
chemerin TACAGGTGGCTCTGGAGGAGTTC CTTCTCCCGTTTGGTTTGATTG 
Mouse 
cyclophilin A GAGGTGTTTGCAGACAAAGTTC CCCTGGCACATGAATCCTGG 
Human 
 IL-1β TACCTGTCCTGCGTGTTGAA TCTTTGGGTAATTTTTGGGATCT 
Human TNFα GAGTGACAAGCCTGTAGCCC ATGTTGTAGCA 
GGCAATGATGATCCCAAAGTAGAC 
CTGCCCAGACT 
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2.3 Single nucleotide polymorphisms in the ChemR23 gene and 
susceptibility to coronary artery disease 
Unpublished data 
2.3.1 Introduction 
A leading cause of mortality worldwide, coronary artery disease (CAD) is caused by plaque 
formation in the intima of mid-sized and large blood vessels – a process termed 
atherosclerosis. Atherosclerotic plaques are marked with lipid retention and chronic 
inflammation in the plaque [95], and it has been suggested that the progression of the 
atherosclerotic plaque development is propelled by impaired resolution of inflammation 
within the plaque [102].  
Macrophages are important players in the pathology of the atherosclerotic plaque. They 
infiltrate the vascular intima taking up oxidized LDL-cholesterol particles during plaque 
formation initiation [90]. Lipid laden macrophages, so called foam cells, and activated 
macrophages then fill the center of the plaque. They secrete a spectrum of inflammatory 
cytokines and chemokines, which activate other cells within the plaque and attract further 
immune cells from the circulation, increasing the inflammatory milieu in the plaque [182]. On 
the other hand, macrophages play a key role in the resolution of inflammation and can have a 
beneficial function in atherosclerosis. Alternatively activated macrophages (M2 macrophages) 
clear apoptotic cells by phagocytosis preventing necrosis within the plaque [183], and 
synthesize matrix repair proteins that stabilize vulnerable plaques [184]. In addition, the anti-
inflammatory cytokines IL-10 and TGFβ typically secreted by M2 macrophages have been 
shown to be atheroprotective [100,185].  
ChemR23 is a G-protein coupled receptor expressed on monocytes and macrophages [128]. It 
binds two ligands – the peptide chemerin and the lipid resolvin E1 (RvE1) [47,135]. 
Chemerin is secreted in inflamed tissue and serves as a chemoattractant of ChemR23 
expressing cells contributing to the initiation of inflammation [136]. Chemerin has been 
detected in atherosclerotic plaques and epicardial adipose tissue [186,187], and both chemerin 
and its receptor ChemR23 are expressed on foam cells [188]. RvE1 is a metabolite of the 
omega-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid and has proresolving 
properties [33]. It induces macrophage phagocytosis of pathogens and apoptotic neutrophils 
[48]. In addition, RvE1 likely one of the mediators of beneficial effects of dietary PUFA [31], 
which have been shown to have cardio-protective role [189].  
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The above mentioned findings lead us to the assumption that as a receptor of chemerin and 
RvE1, ChemR23 plays an important role in the course and resolution of inflammation within 
atherosclerotic plaques. We therefore hypothesized that functional polymorphisms in the 
ChemR23 gene will alter these processes and thus may have an impact on the onset and/or 
course of atherosclerosis. Here, we screened both promoters and the single coding exon of the 
ChemR23 gene for polymorphisms, and investigated their association with CAD in a case-
control study. 
2.3.2 Material and Methods 
Case control study 
A total of 328 men and 149 women from Zurich volunteered to participate in the study. They 
all signed an informed consent form. The study was approved by the local Ethics Committee  
and complies with the Declaration of Helsinki. The case group consisted of 249 consecutive 
Caucasian patients with angiographically documented CAD with more than 50% stenosis in at 
least 1 coronary artery. The control group consisted of 228 Caucasians with angiographically 
negative results and individuals with no history of CAD, stroke, or peripheral vascular disease 
recruited from the general population. Risk factors and the use of medication were assessed 
by a questionnaire. Clinical chemistry analyses were carried out on a Roche-Hitachi Modular 
Clinical Chemistry analyzer using commercial tests from Roche Diagnostics (Rotkreuz, 
Switzerland). The case-control study has a power of 25% - 80% to detect an odds ratio (OR) 
of 1.7 for minor allele frequencies of 5-30%. 
Sequencing 
All three analyzed regions were sequenced on the 3130xl Genetic Analyzer (Applied 
Biosystems). After amplification of the fragments by PCR, sequencing reaction was 
performed with 3 µl purified PCR products in 10 µl reaction volume with the BigDye 
Terminator v 1.1 Cycle Sequencing Kit (Applied Biosystems) according to the manufacturer’s 
instructions. The primers used are listed in Table 2.3.. 
Table 2.3: Primers for PCR and sequencing, 5´- 3´ 
Region Forward primer Reverse primer 
Promoter 1 TTAACAGGCAAGGACAGCACT CCAAGGCAAGTGTGTGATGA 
Promoter 3 TTGGGGCCACCAAAGGCACC CCCACCTCCCTATGTTAGTTC 
Coding 
region CTGGCATGTAGGAGGTACCAGAG TGGCCTGTATCTTCACTTAGAGC 
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Statistical analysis 
The statistical analysis was performed using the R software 2.12.0. The association of SNPs 
with CAD were analyzed by binary logistic regression in an additive genetic model adjusted 
for sex and age. P-values lower than 0.05 were considered statistically significant. The 
haplotype and linkage analysis were performed with Haploview 4.2. 
2.3.3 Results 
To investigate whether polymorphisms in the ChemR23 gene are associated with 
atherosclerosis, we screened in 100 individuals the coding region, the non-coding exon 1, and 
the promoters P1 (chromosome 12, 12q24.1, upstream of 108733094) and P3 (upstream of 
108711724), which we have previously characterized as active in monocytes and 
macrophages. Table 2.4 summarizes the detected polymorphisms and their allele frequencies.  
Table 2.4: Summary of found SNPs 
Location SNP Minor allele frequency (%) 
Promoter 1 
 
T>C 
rs73403360 
0.4%  
(private mutation) 
Exon 1 c.- 192 - 195 del AGAA 
0.4% 
(private mutation) 
 c.- 161 del C 0.7% 
Promoter 3 G>A rs1399821 2.9% 
 T>C rs1399820 67.8% 
 G>A rs11113814 2.9% 
 T>C rs184437753 
0.1%  
(Private mutation) 
 A>G rs10735428 68.0% 
Coding 
region 
T>G 
rs141421422 0.3% 
 T>C rs192034694 0.8% 
 C>T rs61740671 2.3% 
 C>T rs146650378 
0.1%  
(private mutation) 
 G>C rs1057401 43.7% 
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Subsequently, we sequenced the coding region and the promoter region P3, where single 
nucleotide polymorphisms (SNPs) with sufficient frequencies were found to be analyzed for 
association with CAD in our case-control study. In the promoter P3, two pairs of variations 
were shown to be inherited together: rs1399821 and rs11113814 were 100% linked in our 
sample, and rs1399820 and rs10735428 were linked in 98%. The C allele of rs1399820 was 
significantly associated with CAD (OR = 1.36; confidence interval (CI) = 1.02 – 1.81; p-
value: 0.034), and there was a trend for association for the G allele of rs10735428 with CAD 
(OR = 1.27; CI = 0.96 – 1. 69; p-value: 0.094) (Table 2.5A). However, both rs1399820 and 
rs10735428 were not in Hardy-Weinberg equilibrium in controls, which showed higher 
numbers of the homozygote of the minor allele. (In a dominant model, the C and G are more 
strongly associated with atherosclerosis). None of the variations changes any predicted 
transcription factor binding site as analyzed using MatInspector from Genomatix [190]. The 
rs1399820 is predicted to create a new binding site for the SAM pointed domain containing 
transcription factor from the ETS family.  
In the coding region, no significant association between the detected polymorphisms and 
CAD was observed. However, the non-synonymous polymorphism rs192034694 showed a 
trend to increase the risk for CAD (OR = 3.8; CI = 0.79 – 27.60; p-value: 0.12) (Table 2.5B). 
In addition, this polymorphism causes the change of isoleucine to threonine at the position 64, 
which is located in the predicted 1st transmembrane domain (source: UniProt [191]) and is 
rated as damaging by the software PolyPhen-2 [192]. The non-synonymous polymorphism 
rs1399821 leads to the exchange of isoleucine to serine in the same domain and was also rated 
damaging by PolyPhen-2. However, it’s frequency is too low to establish a reliable 
association with CAD in the presented case-control study. 
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Table 2.5: Logistic regression models predicting case status 
A. Promoter P3 
 
Allele 
frequency 
(%) 
Genotype 
Controls 
Genotype 
Cases 
Odds 
ratio 97.5%CI 
p-
value
G>A 
rs1399821 
G: 97.1 
A: 2.9 223 / 10 / 0 238 / 16 / 1 1.91 0.86 – 4.57 0.123
T>C 
rs1399820 
T: 32.2  
C: 67.8 34 / 91 / 103 17 / 113 / 119 1.36 1.02 – 1.81 0.034
G>A 
rs11113814 
G: 97.1  
A: 2.9 223 / 10 / 0 238 / 16 / 1 1.91 0.86 – 4.57 0.123
A>G 
rs10735428 
A: 32.0  
G: 68.0 33 / 89 / 106 19 / 111 / 119 1.27 0.96 – 1. 69 0.094
B. Coding region 
T>G 
rs141421422 
T: 99.8  
G: 0.2 227/ 1 / 0 248 / 1 / 0 0.96 0.04 – 24.80 0.97 
T>C 
rs192034694 
T: 99.2  
C: 0.8 226/ 2/ 0 243 / 6 / 0 3.80 0.79 – 27.60 0.12 
C>T 
rs61740671 
C: 97.7  
T: 2.3 215 / 13 / 0 240 / 9 / 0 0.50 0.20 – 1.24 0.14 
G>C 
rs1057401 
G: 56.1  
C: 43.9 70 /120 / 38 80 / 115/ 54 1.08 0.82 – 1.41 0.58 
 
Logistic regression using an additive genetic model adjusted for age and sex.  
P values < 0.05 are considered significant. 
 
Haplotype analysis of all detected SNPs has shown a high recombination frequency between 
the promoter P3 and the coding region. We observed 6 haplotypes with a frequency >1%. The 
haplotype frequencies are outlined in Table 2.6. None of the haplotypes was associated with 
CAD. 
Table 2.6: Observed haplotypes  
Haplotype 
1 
Haplotype 
2 
Haplotype 
3 
Haplotype 
4 
Haplotype 
5 
Haplotype 
6 
rs1399821 G G A A G G 
rs1399820 G G G G A A 
rs11113814 C C T T C C 
rs10735428 G G G G A A 
rs141421422 T T T T T T 
rs192034694 T T T T T T 
rs61740671 C C C C C C 
rs1057401 G C G C C C 
Frequency 0.56 0.26 0.16 0.14 0.02 0.02 
 
 76
2.3.4 Discussion 
We have scanned the coding region, exon 1 and two promoters of the ChemR23 gene for 
polymorphisms, and analyzed their association with atherosclerosis in a CAD case-control 
study. The polymorphism rs1399820 was significantly associated with CAD in our case 
control study. However, as the odds ratio is relatively low, we assume that this association 
might be due to chance rather than a real association, although  in-silico analysis showed that 
rs1399820 might create a new binding site for the SAM pointed domain ETS factor (SPDEF). 
SPDEF belongs to the Ets family of transcription factors that regulate many developmental 
processes including cell lineage specification, proliferation, differentiation, angiogenesis, and 
apoptosis [193]. Impaired activation and expression of SPDEF has been associated with 
prostate and breast cancer [194,195]. SPDEF is highly expressed in epithelial cells of lung, 
prostate, intestine and mammary glands [196] but it is unclear whether it is expressed by 
mononuclear cells. Therefore this possible creation of a new binding site might not be relevant 
in monocytes and macrophages. A transcription activity assay will have to be done to 
establish, whether this SNP changes the activity of the promoter P3 in macrophages.  
In the coding region, two relatively rare SNPs were detected (rs192034694 and rs141421422), 
causing a change of an amino acid in the predicted 1st transmembrane domain. Both of these 
changes were classified as deleterious in a in silico analysis using the software PolyPhen-2. In 
addition, rs192034694 showed a trend to increase the risk for CAD. A larger study would be 
necessary to confirm the association of this polymorphism with CAD. In addition, it would be 
desirable to analyze the impact of both rs192034694 and rs141421422 on the functionality of 
the receptor. This could be done by performing chemerin chemotaxis assay with macrophages 
from carriers of these SNPs or measuring chemerin triggered calcium release in SNP bearing 
ChemR23 transfected cells [133]. 
In conclusion, the promoter variation rs1399820 showed an association while the the non-
synonymouse coding region variation rs192034694 showed a trend for association with CAD. 
The variations may have an impact on the regulation and functionality of ChemR23, 
respectively. Further in vitro studies would be necessary to confirm the predicted effects. In 
addition, a larger case-control study will be necessary to confirm their association with CAD.  
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3 Discussion 
ChemR23 expression and function in differentially activated macrophages 
A receptor of the lipid mediator resolvin E1, and of the chemoattractant and adipokine 
chemerin, ChemR23 has a role in the resolution of inflammation, chemotaxis of mononuclear 
cells to the inflamed area, and in adipogenesis. In addition, the ChemR23 - chemerin axis has 
been proposed to present a link between obesity and excessive accumulation of inflammatory 
leukocytes in the adipose tissue [146]. Yet, there is little known about the regulation of 
ChemR23 expression during the course of inflammation or in response to inflammatory and 
anti-inflammatory stimuli.  
We show that ChemR23 expression increases during monocyte differentiation to 
macrophages and is further induced by inflammatory stimuli. Naive and inflammatory M1 
macrophages are thus chemotactic toward chemerin and respond to RvE1 signaling by the 
increase of IL-10 transcription. In contrast, anti-inflammatory M2 macrophages do not 
express ChemR23 and are not responsive to chemerin.  
Macrophages are after adipocytes one of the most abundant cell types in the adipose tissue. 
Increased infiltration of monocytes/macrophages into the adipose tissue is associated with 
obesity [197,198]. In addition, these macrophages have mostly the M1 phenotype in contrast 
to M2 macrophages, which populate the lean adipose [79,199]. Chemerin is highly secreted 
by mature adipocytes and chemerin secretion from the adipose tissue has been shown to 
increase with increasing body weight [172]. This adipocyte secreted and activated chemerin 
[138] is likely to contribute to the inflammatory status of obese adipose tissue by attraction of 
macrophages. Our results support this notion showing that only naive and inflammatory but 
not M2 macrophages express ChemR23 and thus can migrate toward chemerin. M1 
macrophages secrete increased amounts of inflammatory cytokines such as TNFα and IL-1β, 
which signal to adipocytes in a parakrine manner. We show that these inflammatory cytokines 
increase chemerin transcription and secretion in adipocytes possibly creating a vicious circle. 
On the other hand, RvE1 in our experiments increases IL-10 transcription in M1 macrophages 
leading to an intermediate phenotype and revealing a possible role of RvE1 in the resolution 
of adipose tissue inflammation.  
Anti-inflammatory actions of low dose aspirin 
Coronary artery disease is tightly associated with inflammation manifesting itself by increased 
CRP and IL-6, and reduced IL-10 levels in plasma [101,200,201,202]. We show that 
chemerin plasma levels in CAD patients not treated with aspirin are significantly increased in 
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comparison to patients on low dose aspirin and to healthy controls. In vitro, low dose aspirin 
treatment decreased the secretion of IL-1β and IL-6 and increased the anti-inflammatory IL-
10 in M1 activated macrophages but had no direct effect on chemerin expression in the major 
chemerin secretors hepatocytes and adipocytes [124,143]. Chemerin secretion is upregulated 
by IL-1β and TNFα  in adipocytes but mildly reduced in hepatocytes. This indicates that 
inflammation will increase chemerin secretion from adipocytes while the anti-inflammatory 
effect of low dose aspirin on macrophages may result in reduced systemic and adipose tissue 
inflammation leading to reduced chemerin secretion. In line with our finding, reduced IL-1β 
plasma levels have been observed after 2 months of low dose aspirin treatment in patients 
with hypercholesterolemia [203]. To confirm that low dose aspirin reduces systemic and 
adipose tissue inflammation it would however be important to assess whether it reduces IL-1β 
and IL-6 and increases IL-10 in plasma and/or within the adipose tissue. Unfortunately, we 
were not able to do these measurements in our CAD case-control study. Nevertheless, we 
observed a trend in CRP reduction in low dose aspirin treated patients. However, as the group 
not on aspirin was relatively small the two groups were too unequal for detecting a 
statistically significant difference. Further research will be necessary to confirm that low dose 
aspirin treatment reduces adipose inflammation and so chemerin secretion from adipose tissue 
in vivo. It would be expecially interesting to analyze whether low dose aspirin treatment 
affects plasma concentrations of chemerin and inflammatory markers in obese patients and 
whether adipose tissue explants secrete lower levels of chemerin and/or inflammatory 
cytokines in response to aspirin treatment. 
We show that aspirin down-regulates IL-1β on the transcription level while it has no effect on 
TNFα transcription and secretion. Classically, secretion of inflammatory cytokines including 
TNFα and IL-1β is induced in macrophages after LPS binding to the TLR-4 receptor through 
activation of the MyD88-dependent signaling pathways. This leads to NF-κB translocation to 
the nucleus and to initiation of transcription [204,205]. Previously, aspirin has been reported 
to block NF-κB signaling [206] and inhibit TNFα expression in mouse primary macrophages 
[207]. Therefore, it could be expected that aspirin treatment reduces both TNFα and IL-1β. 
However, the aspirin concentrations used in all previous experiments were 100 – 1000 times 
higher that the concentrations corresponding to low dose of aspirin treatment used in our 
experiment. The fact that low dose aspirin reduces IL-1β but not TNFα transcription in our 
experiments, indicates that low dose aspirin acts in a NF-κB independent manner. Such a 
pathway was recently described in a study showig that LPS-stimulated IL-1β transcription is 
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specifically regulated by the hypoxia induced factor HIF-1α. The inhibition of HIF-1α 
stabilization with succinate suppressed LPS-induced IL-1β but not TNF-α [208].  
We further report that aspirin treatment increases IL-10 secretion in M1 macrophages. IL-10 
was previously shown to have anti-inflammatory effects on mouse 3T3 adipocytes 
suppressing the production of CCL2 and antagonizing the effect of TNFα in a NF-kB 
independent manner in these cells [80]. The aspirin stimulated increase in secretion of IL-10 
in M1 macrophages obeserved in our experiments might thus contribute to reduction of 
chemerin secretion in adipose tissue. The effect of IL-10 on human adipocytes has to be 
however further studied because the IL-10 receptor was shown to be transcribed in human 
adipocytes [73] but its presence on the surface of human adipocytes has been questioned 
[73,80,209]. 
Finally, aspirin treatment of M1 macrophages also lead to reduction of IL-6 secretion. IL-6 is 
a pleyotropic cytokine increased in plasma during obesity and systemic inflammation [210], 
and increased IL-6 levels in plasma have been associated with increased risk for myocardial 
infarction [211]. Although IL-6 does not directly affect chemerin transcription and secretion 
in adipocytes, the decrease of its secretion by M1 macrophages can serve as an additional 
indication that low dose aspirin indeed reduces the inflammatory status of these macrophages. 
In line with our finding, low dose aspirin treatment was shown to reduce IL-6 levels in obese 
individuals and the IL-6 secretion by white adipose tissue [212] further supporting the notion 
that low dose aspirin might reduce systemic and adipose tissue inflammation.  
Aspirin is a multifunctional drug and has, next to the reported anti-inflammatory effects on 
macrophages, systemic effects on different cell types and tissues in the body. Aspirin 
triggered resolvins and lipoxins secreted by different tissues after the intake of aspirin are 
likely additional explanation for the anti-inflammatory effect of low dose aspirin [213,214]. 
Resolvins and aspirin-triggered resolvins were in addition shown to have a beneficial effect 
on inflammation associated with obesity. Resolvins of the D-type have been reported to 
improve the inflammatory status of obese adipose tissue by increasing adiponectin secretion 
and decreasing TNFα, IL-6 and IL-1β secretion in mouse adipose tissue explants [63,215]. In 
addition, stimulation of LPS activated mouse M1 macrophages with RvD1 decreased TNFα 
and IL-6 secretion and increased arginase 1 expression (mouse M2 macrophage marker) in a 
way similar to IL-4 re-stimulation [215]. Although the receptor of RvE1 is expressed on both 
adipocytes and M1 macrophages, its direct effects in adipose tissue have not been studied. 
However, intraperitoneal injection of RvE1 had an insulin sensitizing effect on the adipose 
tissue by inducing adiponectin, glucose receptor (GLUT-4), insulin receptor substrate (IRS-1) 
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and PPARγ expression in ob/ob mice [64]. Whether this effect was due to RvE1 signaling on 
adipocytes or in macrophages is not clear. We show that RvE1 increased anti-inflammatory 
IL-10 transcription in human M1 macrophages. This was in contrast to IL-4 signaling in 
human M1 macrophages which had no impact on IL-10 transcription but lead to increased 
CD206 expression. This indicates that RvE1 signals in a different way than IL-4 and does not 
lead to M2 phenotype in macrophages but rather to an intermediate phenotype. Such 
macrophage phenotype has been described during the resolution phase of zymosan induced 
murine peritonitis [5]. Further experiments have to follow to show whether RvE1 has anti-
inflammatory or proresolving effects on adipocytes, and macrophages within the adipose 
tissue by analyzing the impact of RvE1 on adipocytes and adipose tissue explants in culture.  
Use of alternative promoters and alternative splicing of the ChemR23 mRNA in macrophages 
Up to now the promoter region of ChemR23 has not been characterized in humans. We have 
identified two promoters (P1 and P3) active in human monocytes and macrophages, and 1 
additional putative promoter (P2) with low activity in macrophages. A recent large scale 
computational analysis of 5´end sequences of putative full length cDNAs revealed that more 
than 50% of human genes are transcribed from alternative promoters [216]. Similar to 
ChemR23, in many genes where alternative promoter usage has been experimentally 
confirmed, no variation in the translated protein has been reported [217]. Instead, the use of 
alternative promoters is a means of diversification of transcription regulation in different cell 
types, different developmental stages or in response to different stimuli [218]. In the case of 
ChemR23, the identified putative promoter P2 with low activity in macrophages may allow 
differential regulation of transcription of ChemR23 in adipocytes or endothelial cells, where 
ChemR23 has been shown to be also highly expressed [125,143]. In monocytes and 
macrophages, ChemR23 alternative promoter usage leads to transcription of 2 alternative first 
exons. Additionally, mRNAs transcribed from promoter P1 undergo alternative splicing 
leading to 2 mRNAs variants in macrophages and 3 in monocytes. This alternative splicing of 
the 5´untranslated region (UTR) of mRNAs enables tight regulation of mRNA translation 
through different stability or variable translation efficiency of individual isoforms [218]. We 
have previously shown that the 5´UTR of the LXA4 receptor (FPR2) is differentially spliced 
leading to mRNA isoforms with different translation efficiencies in human monocytes and 
macrophages [219]. It is likely that the alternative splicing of the non-coding exons in 
ChemR23 mRNA has a similar function. A luciferase activity assay with different 5´UTR 
fragments subcloned between the SV40 promoter and the luciferase gene could be done to 
analyze the translation efficiency of individual mRNA isoforms.  
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Conclusion 
To conclude, we show that ChemR23 expression is tightly regulated in monocytes and 
macrophages. ChemR23 expression is upregulated during monocyte differentiation to 
macrophages and further amplified by inflammatory stimuli. In contrast, ChemR23 is not 
present on the membrane of M2 macrophages. Our data support ChemR23 function in 
chemotaxis of monocytes, and naive and inflammatory M1 macrophages. On the other hand, 
M2 macrophages, which have anti-inflammatory properties and are associated with wound 
healing and tissue repair [13] were not responsive to ChemR23 mediated stimuli in our 
experiments. We therefore surmise that the proresolving actions of RvE1 are mediated 
through ChemR23 in naive or inflammatory M1 macrophages. A direct re-polarization of M1 
to M2-like macrophage phenotype stimulated by cytokines was documented in vitro [19,220]. 
A switch of macrophage phenotypes has been also observed during transition of acute to 
resolving inflammation in vivo [14]. We show that RvE1 increases IL-10 transcription in M1 
macrophages shifting them toward an anti-inflammatory phenotype. However, IL-10 secretion 
is not increased after 4 days of RvE1 treatment. It is possible that RvE1 acts more rapidly and 
IL-10 is increased earlier after RvE1 application. A time-course measurements of IL-10 in the 
macrophage media could be done to show whether this is the case. On the other hand, RvE1 
might act only as a subtle stimulus on macrophages and a more complex tissue context might 
be needed to achieve a complete re-polarization for example in response to other signals 
triggered by RvE1 through ChemR23 on endothelial cells [125] and through BLT1 on 
neutrophils [49]. In addition, it has been shown that macrophage efferocytosis (phagocytosis 
of dead cells and of cellular debris) induced the switch of macrophage phenotype toward a 
pro-resolving one, and increased IL-10 secretion [221,222,223]. RvE1 accelerated this switch 
of macrophage phenotype by reducing the efferocytic requirement for it [222]. Therefore a 
combination of efferocytosis and RvE1 triggering might be neccessary for a full re-
polarization of macrophages to a pro-resolving phenotype. 
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